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ABSTRACT 
Surveillance is the primary means to generate information on the presence and/or distribution 
of pathogens in animal populations.  Fulfillment of this function is ultimately dependent on 
the program’s ability to collect, test, aggregate, and analyze data from individual samples.  
The problem addressed in this dissertation is whether oral fluid specimens could be used to 
surveillance and monitor individually-based and pen-based for porcine reproductive and 
respiratory syndrome virus (PRRSV) infection.  In particular, but not exclusively, the aim of 
this research was to evaluate the oral fluid emzyme-linked immunosorbent assay (ELISA) 
could be used to detect anti-PRRSV antibody isotypes.  This problem was addressed in the 
logical series of experiments described below.     
 
The objective of the Chapter 3 was to evaluate a commercial serum antibody ELISA 
performance that was modified to detect anti-PRRSV antibodies in pen-based oral fluid 
specimens.  Experimental and field oral fluid samples from defined PRRSV infection status 
were used to derive the kinetics of detectable concentrations of antibody against PRRSV.  
IgM and IgA were readily detected in oral fluid specimens from populations in which 
PRRSV infection was synchronized among all individuals, but not in samples collected in 
commecial herds.  In contrast, IgG was readily detected at diagnostically useful levels in both 
experimental and field samples for up to 126 days (duration of the study).  Estimates of the 
IgG oral fluid ELISA performance were based on results from testing positive oral fluid 
samples (n = 492) from experimentally inoculated pigs (n = 251) and field samples (n = 241), 
and negative oral fluid samples (n = 367) from experimentally inoculated pigs (n = 84) and 
field samples (n = 283).  ROC analysis estimated the diagnostic sensitivity and specificity of 
the assay as 94.7%  (95% CI: 92.4, 96.5) and 100% (95% CI: 99.0, 100.0), respectively, at a 
sample:positive (S/P) ratio cutoff of  ≥ 0.40.  The results of this study suggest that the IgG 
oral fluid ELISA can provide efficient, cost-effective PRRSV monitoring in commercial 
herds and PRRSV surveillance in elimination programs. 
 
Chapter 4 addressed the repeatability and reproducibility of oral fluid antibody ELISA.  The 
precision of a PRRSV oral fluid antibody ELISA was evaluated by calculating reliability 
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coefficients for assay repeatability (within laboratory) and assay reproducibility (between 
laboratories).  Randomly ordered oral fluid samples from known (n = 39) and unknown (n = 
224) PRRSV antibody status were tested in 12 diagnostic laboratories.  Each laboratory 
tested the samples twice, first using an antibody ELISA kit and reagents provided to them 
(Phase 1) and then using an ELISA kit and reagents configured in their laboratory (Phase 2).  
Repeatability (within laboratory) reliability coefficients calculated using results from samples 
from known PRRSV antibody status ranged from 0.724 to 0.997 in Phase 1 and 0.953 to 
0.998 in Phase 2.  Reproducibility (between laboratories) reliability coefficients were 
calculated for three conditions: Case 1 - samples of unknown status (n = 224); Case 2 - 
samples from known status (n = 39), and Case 3 - all samples (n = 263).  Among the three 
cases, reliability coefficients ranged from 0.937 to 0.964 in Phase 1 and 0.922 to 0.935 in 
Phase 2.  For Case 3, it was estimated that 96.7% of the total variation in Phase 1 and 93.2% 
in Phase 2 could be attributed to the oral fluid samples themselves.  Overall, the PRRSV oral 
fluid antibody ELISA was highly repeatable and reproducible.  This study supported the 
routine use of this test in laboratories providing diagnostic service to pig producers. 
 
The study objective outlined in Chapter 5 was to describe and contrast the kinetics of the 
humoral response in serum and oral fluid specimens during acute PRRSV infection.  The 
study was done in three trials with 24 boars used in each trial.  Boars were intramuscularly 
(IM) inoculated with a commercial modified live virus (MLV) vaccine (Trial 1), a Type 1 
PRRSV field isolate (Trial 2), or a PRRSV Type 2 field isolate (Trial 3).  Oral fluid samples 
were collected from individual boars on day post inoculation (DPI) -7 and daily for 21 DPI.  
Serum samples were collected from all boars on DPI -7, 0, 7, 14, 21 and from 4 randomly 
selected boars on DPIs 3, 5, 10, and 17.  Thereafter, serum and oral fluid were assayed for 
PRRSV antibody using antibody isotype-specific ELISAs (IgM, IgA, IgG) adapted to serum 
or oral fluid.  Statistically significant differences in viral replication and antibody responses 
were observed among the three trials in both serum and oral fluid specimens.  Anti-PRRSV 
antibody isotype responses in serum (IgM, IgA, and IgG) were first detected in samples 
collected on DPI 7, 10, and 10, respectively.  Oral fluid IgM, IgA, and IgG were detected in 
samples collected between DPI 3 to 10, 7 to 10, and 8 to 14, respectively.  This study 
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enhanced the scientific knowledge concerning the pig’s the humoral immune response to 
PRRSV and provided a broader foundation for understanding, interpreting, and developing 
oral fluid antibody-based diagnostics. 
 
The objective for the study described in Chapter 6 was to assess oral fluid samples use when 
collected from piglets prior to weaning as a method to monitor sow herd PRRSV antibody 
and infection status.  Samples originated from four ~12,500 sow herds.  All four herds were 
considered endemically infected with PRRSV based on historic diagnostic data.  Oral fluid 
samples were collected from 600 litters prior to weaning and serum samples from their dams 
after weaning.  All samples were randomized and tested for PRRSV antibodies (IgM, IgA, 
IgG and PRRS X3 Ab Test or PRRS Oral Fluids Ab Test) and PRRSV (RT-qPCR and 
sequencing).  Results were analyzed for associations with sow parity, litter size, and farm by 
analysis of variance (ANOVA) and correlation analyses.  No sow serum samples were 
positive for PRRSV by RT-qPCR, but 9 of 600 oral fluid samples were confirmed positive by 
PRRSV RT-qPCR testing at two laboratories.  Two were successfully sequenced (ORF5) and 
identified as wild-type PRRSV.  This study showed that piglet oral fluid samples are a useful 
and sensitive approach for monitoring PRRSV circulation in endemically infected and/or 
vaccinated herds, as well as for monitoring the PRRSV status in PRRSV negative herds.   
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CHAPTER 1.  INTRODUCTION: DISSERTATION ORGANIZATION 
This dissertation consists of 7 chapters.  The first chapter is the dissertation organization.  
Chapter 2 is the general introduction and review of the literature, "Disease surveillance and 
monitoring systems – challenges to implementing surveillance in contemporary production 
systems”.  Chapter 3, “Detection of porcine reproductive and respiratory syndrome virus 
(PRRSV) antibodies in oral fluid specimens using a commercial PRRSV serum antibody 
ELISA” was published in the Journal of Veterinary Diagnostic Investigation.  Chapter 4, 
“Ring test evaluation of the repeatability and reproducibility of a porcine reproductive and 
respiratory syndrome virus (PRRSV) oral fluid antibody enzyme-linked immunosorbent 
assay" was published in the Journal of Veterinary Diagnostic Investigation.  Chapter 5, 
"Kinetics of the porcine reproductive and respiratory syndrome virus (PRRSV) humoral 
immune response in swine serum and oral fluids collected from individual boars" was 
publisehd in BMC Veterinary Research.  Chapter 6, “Porcine reproductive and respiratory 
syndrome virus (PRRSV) surveillance using pre-weaning oral fluid samples detects 
circulation of wild-type PRRSV” has been submitted for publication in Veterinary 
Microbiology.  References, tables, and the figures associated with each chapter follow the 
discussion section.  The final chapter contains the General Conclusions of the dissertation. 
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CHAPTER 2.  DISEASE SURVEILLANCE AND MONITORING SYSTEMS - 
CHALLENGES TO IMPLEMENTING SURVEILLANCE IN CONTEMPORARY 
PRODUCTION SYSTEMS 
 
A manuscript to be submitted to the Journal of Swine Health and Production 
Apisit Kittawornrat 
 
SUMMARY 
Surveillance is the primary means for generating information on the presence and/or 
distribution of pathogens in animal populations (Hadorn and Stärk, 2008).  Fulfilling this 
function is ultimately depends on the program’s ability to collect, test, aggregate, and analyze 
data from individual samples.  Herein the background, requirements, and challenges 
associated with surveillance sampling from swine populations in field production situations 
are reviewed.    
 
INTRODUCTION 
According to Thrusfield (2005), "monitoring" consists of routine observations on health, 
productivity, and other characteristics related to them in a population, whereas "surveillance" 
is a more intensive form of data collection than monitoring.  Thrusfield (2005) identified 
three components in disease surveillance: (1) gathering, recording, and analysis of data, (2) 
communication of information, and (3) response(s) to actionable thresholds, e.g., 
intervention(s) for the purpose of disease control.  Although monitoring and surveillance are 
often used interchangeably in common language, the third component (response) 
differentiates monitoring from surveillance.  For simplicity, monitoring and surveillance 
systems are increasingly referred to as "MOSS" (Salman, 2003).   
 
The first task in designing a MOSS for infectious diseases is to precisely define its objective, 
e.g., detection, prevalence estimation, process control, etc.  The second task is to define the 
population to be surveilled, e.g., barn, site, system, or region.  Thereafter, the design is built 
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on this foundation:  the type of specimen, the collection method, the number of samples, the 
diagnostic test(s) to be used to analyze the samples, and the methods to be used to analyze 
the data.  For surveillance, actionable thresholds and specific responses must also be defined.   
 
BASIC SAMPLING PRINCIPLES 
The idea that a subsample of a population could provide valid estimates of an entire 
population is relatively new.  As reviewed by Kruskal and Mosteller (1980), A.N. Kiaer, 
Director of the Norwegian Central Bureau of Statistics, proposed the idea of ‘representative 
sampling’ at the Berne meeting of the International Statistical Institute in 1895 (Kruskal and 
Mosteller, 1980).  Kiaer believed that national social and economic data could be obtained by 
studying a subset rather than the entire population.  The concept was not well received by the 
experts of the time, but nevertheless continued to move forward.  In 1912, L. von 
Bortkiewicz introduced a significance test to evaluate the representativeness of the sample 
subset to the population as a whole.  Around the same time, L. March added the concept of 
probability sampling to the discussion, but nonprobability sampling (purposive methods) 
remained the norm for a time.  As reviewed by Frankel and Frankel (1987), probability 
sampling began in earnest with a 1934 publication on the topic by J. Neyman and was 
cemented firmly in place by a large-scale, probability-based study on unemployment in the 
United States conducted by the Work Projects Administration in 1939.   
 
MOSS sampling methods are either probability or nonprobability based.  Nonprobability 
sampling occurs when some individuals in the population have no chance of selection.  
Nonprobability sampling methods include convenience sampling, volunteer sampling, 
judgment sampling, or quota sampling (Dahoo et al, 2009).  Nonprobability sampling 
methods offer simplicity, expediency and low cost, but are susceptible to both random and 
systematic bias and may not provide data amenable to valid statistical analyses.   
 
Probability sampling requires that every individual in the population have a defined, non-
zero chance of being selected and that random selection is conducted at some point in the 
process.   
4 
 
 
Probability sampling methods include simple random sampling, systematic sampling, 
stratified random sampling, cluster sampling, and multistage sampling.  Since units from the 
population are randomly selected and each unit’s probability of inclusion can be calculated, 
statistically valid estimates and inferences can be made about the population.  However, 
probability sampling is usually more complex, time-consuming and expensive than non-
probability sampling.  As described by Cochran (1977), probability sampling procedures 
must conform to key statistical principles:  
 
1.  The set of individuals of which the population is composed can be precisely identified 
and all individuals have an equal probability of selection.   
2.  Every individual within the population has a known probability of selection. 
3.  Sample selection is conducted by a random process.   
 
In swine populations, sampling the entire population of interest is necessary and practical in 
some situations, e.g., testing the entire group of replacements due to enter an expected-
negative sow farm or boar stud.  Pragmatically, sampling an entire swine population is 
generally impossible and, therefore, it is necessary to determine the appropriate number of 
individuals to sample.  Although there are several approaches for the calculation of sample 
size, four factors are paramount: (1) the purpose of sampling, e.g., to detect positive animals 
in an expected negative herd or to estimate herd level prevalence, (2) the desired accuracy 
and confidence level of test estimates, (3) the cost of collecting and testing samples, and (4) 
the sensitivity and specificity of the diagnostic test (Chase and Polson, 2000).  As an 
example, the following formula can be used to approximate the sample size required to detect 
at least one positive animal in an infinite population (Cannon and Roe, 1982): 
 
݊ ൌ ୪୭୥ሺଵି௖ሻ୪୭୥ሺଵି௣ሻ     Equation 1 
 
where n is the sample size, c is the confidence level, and p is the expected within-herd 
prevalence.  Estimates based on Equation 1 have published in tables, are available in a 
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variety of software and freeware programs, and have been widely used (Dufresne et al., 
2003).  Notable, Equation 1 is based the assumption that the diagnostic test has perfect 
sensitivity (Se) and specificity (Sp).  Equation 2 takes actual test performance into 
consideration when calculating sample size for an infinite population (Martin et al., 1992):  
 
݊ ൌ ୪୭୥ሺଵି௖ሻሼ୪୭୥ሾୗ୮ሺଵି௣ሻିሺଵିௌ௘ሻ௣ሿሽ    Equation 2 
 
where Se and Sp are diagnostic sensitivity and specificity, respectively.  Software tools have 
also been developed to calculate sample size for finite populations and diagnostic tests with 
imperfect sensitivity and specificity, e.g., FreeCalc® (Cameron and Baldock, 1998).   
 
PROBABILITY SAMPLING IN SWINE POPULATIONS 
Swine farms differ from other populations, especially human populations, in three important 
ways:  (1) the rate of population change on farms, (2) the extensive movement of populations 
between farms, and (3) the physical segregation of groups of animals within the same farm 
population by age and/or production stage or function.  These differences are rarely (if ever) 
accounted for in current MOSS designs, but have important implications for the accuracy and 
timeliness of estimates.   
 
Population change consists of "natural change" (total births minus total deaths) plus 
migration into or out of the population.  Population change in humans typically represents a 
small proportion of the population.  For example, the state of Nebraska recorded a population 
change of +8.4% for the period 1990 to 2000 (Deichert, 2001).  This consisted of a natural 
change of +5.4% and net migration of +3.1%.  In contrast, a finishing barn on a typical farm 
will experience ~250% population change annually as groups of animals enter into the 
facility, grow, and are sent to market.  Extensive movement of animals between sites is part 
of this process.  In particular, pigs are moved from Canadian or US breeding herds into 
finishing operations located in the Midwestern Corn Belt.  As reviewed by Goodell et al. 
(2013), nearly 40,000,000 live swine were moved across state lines in 2011.  Although more 
6 
 
 
stable than growing pig populations, sow herds are not excluded from rapid population 
change.  Typically, ~40% of females in sow herd populations are replaced annually 
(PigChamp® Benchmark, 2011).   
 
Thus, in contrast to human populations, swine populations experience extremely high 
turnover.  This has important implications for herd immunity, the ability of pathogens to 
circulate within them, and the design of sampling protocols that can capture this dynamic.  
These conditions dictate that MOSS sampling be repeated routinely, if the expectation is 
accurate and relevant data.  This assessment is supported by modeling used to simulate the 
effect of sampling frequency on the detection of infections in swine populations.  Polson and 
Jordan (2002) developed a model to compare the detection of porcine reproductive and 
respiratory syndrome virus (PRRSV) infection at three prevalence levels (3%, 5%, and 10%) 
using 4 combinations of sample size and sampling frequency:  60 samples 4 times per year, 
40 samples 6 times per year, 30 samples 8 times per year, and 20 samples 12 times per year.  
Their results showed that smaller sample size at higher sampling frequency was more likely 
to result in detection.  Rovira et al. (2007) developed a stochastic model to compare the 
detection of PRRSV in boar studs as a function of sample size (10, 30, and 60), sampling 
frequency (3 times per week, weekly, and biweekly), and diagnostic procedure (polymerase 
chain reaction (PCR) testing of semen or serum, antibody ELISA testing of serum, or both 
PCR and ELISA testing of serum).  They found that PCR testing of serum detected PRRSV 
infection the earliest.  Specifically, testing serum samples from 60 boars 3 times per week by 
PCR resulted in the detection of 95% of the PRRSV introductions within 13 days.  In general 
terms, Thurmond (2003) recommends that sampling intervals should be shorter for pathogens 
with high effective reproductive rates, for cases in which the sensitivity of the test is low, 
and/or when the costs associated with failure to detect the disease are significant.  However, 
unlike sample size, there is no published formula for calculating the optimum sampling 
frequency.  Therefore, the decision is usually bounded on one side by the urgency of the need 
for the information and by cost constraints on the other (Roberts, 2003). 
 
A separate problem in implementing probability sampling on the farm is compliance with the 
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requirement that animals sampled from the population are randomly selected.  In general, 
farms consist of separate buildings in which animals are segregated by age and/or production 
stage into rooms and pens.  Like sampling frequency, there is no guidance concerning the 
allocation of samples across these physical strata.  Therefore, despite the fact that strata may 
not be homogenous in terms of disease status, it is common for samples to be selected by 
convenience and without formal guidelines.  Most often sampling is conducted under the 
unproven assumption that certain strata are most representative of the farm’s disease status. 
 
SEEKING PRACTICAL SOLUTIONS  
Although the importance of conducting MOSS in compliance with valid statistical principles 
is rightfully stressed (Salman, 2003), non-statistical considerations, e.g., the availability of 
personnel and the cost of collecting, testing, and analyzing data, set concrete limits to the 
procedures that can be implemented on the farm.  For this reason, there is a need for 
approaches that can achieve valid MOSS while satisfying the limits dictated by money and 
time.  Recent work in swine populations has focused on methods of handling specimens that 
reduce costs while maintaining testing performance.  Two examples of this approach are 
pooling of serum samples from individual pigs and the collection of oral fluid specimens 
from individuals or groups.   
 
A pooled sample, also known as a "composite sample" in some disciplines, is created by 
combining equal volumes of two or more sample units into one aliquot for testing (Cameron 
et al., 2003).  The goal of pooling is to detect the presence of a target at a lower cost than 
testing individual samples (Lovison et al., 1994).  This is done in a 2-step process termed the 
"Dorfman procedure" whereby pooled samples are first tested for the presence of the target.  
If the pool tests negative, the individual specimens of which the pool is composed are 
considered negative.  If the pool tests positive, the specimens of which the pool is composed 
are tested individually to determine their status.  (Retesting positive pools results is not 
necessary if determination of population status (positive/negative) is the primary outcome of 
interest.)  The Dorfman procedure was used by the United States Public Health Services 
during World War II to screen military inductees for syphilis (Dorfman, 1943).  Individual 
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blood samples were drawn, pooled in groups of five, and tested the presence or absence of 
“syphilitic antigen.”  When a pool tested positive, each sample in the pool was tested 
individually to identify which of the members were infected.   
 
Pooling continues to be used extensively in disease detection in swine and other species 
(Emmanuel et al., 1988;  Kline et al., 1989; Maherchandani et al., 2004; Muñoz-Zanzi et al., 
2000; Peeling et al., 1998), as well as in human genetics testing (Chowdari et al., 2007), 
because it offers the advantage of reduced testing costs and faster laboratory turnaround time 
as a result of the fact that fewer total assays are performed.  A core issue for pooling is the 
fact that the process of combining one or more positive samples with negative samples 
invariably results in a lower concentration of the analyte (Cameron et al., 2003, Muñoz-Zanzi 
et al., 2006).  The number of individuals that can be pooled while preserving adequate 
detection sensitivity varies by assay, specimen, and pathogen/analyte characteristics 
(Cahoon-Young et al., 1989; Dorfman 1943; Kline et al., 1989).  Commonly, pool size varies 
between 5 and 20 samples.   
 
In swine diagnostics, sample identity (animal identification, physical location, sampling date) 
are typically lost in the process of pooling.  This may not impact the utility of the results for 
producers who are only interested in whether the analyte of interest is present in the 
population, but further statistical analyses or epidemiological interpretations are often limited 
or impossible because of the loss of sample unit identification.  Therefore, MOSS that rely on 
testing pooled samples need to accommodate this potential limitation in their design.   
 
The use of pen-based oral fluid specimens in swine medicine is another approach designed to 
facilitate cost-effective MOSS.  "Oral fluid," a combination of serum transudate and saliva, is 
the liquid collected by placing an absorptive device in the mouth.  As reviewed by Prickett 
and Zimmerman (2010), a variety of pathogens and pathogen-specific antibodies are present 
in swine oral fluid, e.g., classical swine fever virus (Corthier, 1976; Corthier and Aynaud, 
1977), African swine fever virus (Mur et al., 2013), porcine circovirus type 2 (Prickett et al., 
2011), PRRSV (Prickett et al., 2008a,b; Kittawornrat et al., 2012), swine influenza virus 
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(Panyasing et al., 2012), transmissible gastroenteritis virus (DeBuysscher and Berman, 
1980), Actinobacillus pleuropneumoniae (Loftager et al., 1993), Escherichia coli (De 
Buysscher and Dubois, 1978), and others.  In particular, extensive research has been 
conducted on the use of oral fluids for PRRSV diagnostics.  The presence of PRRSV in oral 
fluids was first reported in 1997 (Wills et al., 1997).  In 2008, Prickett and colleagues 
reported the detection of PRRSV nucleic acid and antibodies in oral fluid specimens.  
Subsequent research has corroborated and expanded upon these initial observations 
(Kittawornrat et al., 2010, 2012a,b).   
    
In sampling terminology, an oral fluid sample is best described as a "grab sample" from a 
sample unit (pen).  In this context, “grab sample” is defined as a sample collected “at a 
specific point in time and at a specific location” (Koerner, 1996) and "sample unit" is the 
smallest division of the population and the level at which sample size calculations and 
random sampling procedures are performed (Dohoo et al., 2009; Steele and Torrie, 1980; 
Toma et al., 1999).  Examples of sample units given by Toma et al. (1999) include, “an 
animal, a group of animals, i.e., a pen, a herd ….”  Recently, Olsen et al. (2013) reported that 
pen-based oral fluid samples greatly improved detection over single-animal testing, e.g., 
among 100 oral fluid samples from pens with PRRSV prevalence between 4 to 36%, 62% 
were positive for PRRSV RNA and 61% for PRRSV antibody. 
 
CONCLUSIONS 
Cost-effective methods of MOSS are needed to support animal health and business decisions 
at the herd level, improve the quality of field research, and provide timely information on 
endemic and foreign animal diseases in the national swine herd.  The primary long-standing 
roadblock to this goal is the inconvenience and cost of acquiring the information, i.e., the 
expense of collecting and testing statistically appropriate numbers of blood, feces, or nasal 
swab specimens from individual pigs.  A cost-effective solution to the current health 
information vacuum is vital.  This will require (1) efficient, low-cost specimen collection and 
(2) accurate diagnostic assays.  In particular, we postulate that a surveillance system for 
swine infectious diseases based on oral fluid specimens can be developed to achieve the goal 
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of a comprehensive and integrated swine health surveillance system.   
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CHAPTER 3.  DETECTION OF PORCINE REPRODUCTIVE AND RESPIRATORY 
SYNDROME VIRUS (PRRSV) ANTIBODIES IN ORAL FLUID SPECIMENS USING 
A COMMERCIAL PRRSV SERUM ANTIBODY ELISA  
 
A. Kittawornrat, J. Prickett, C. Wang, C. Olsen, C. Irwin, Y. Panyasing, A. Ballagi, A. Rice, 
R, Main, J. Johnson, C. Rademacher, M. Hoogland, R. Rowland, J. Zimmerman 
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ABSTRACT 
The purpose of the present study was to evaluate the diagnostic performance of a commercial 
serum antibody ELISAa modified to detect anti-porcine reproductive and respiratory 
syndrome virus (PRRSV) antibodies in pen-based oral fluid specimens.  Experimental and 
field oral fluid samples of defined status in reference to exposure of swine with PRRSV were 
used to derive the kinetics of detectable concentrations of antibody against PRRSV.  IgM and 
IgA were readily detected in oral fluid specimens from populations in which PRRSV 
infection was synchronized among all individuals, but not in samples collected in commecial 
herds.  In contrast, IgG was readily detected at diagnostically useful levels in both 
experimental and field samples for up to 126 days.  Estimates of the IgG oral fluid ELISA 
performance were based on results from testing positive oral fluid samples (n = 492) from 
experimentally inoculated pigs (n = 251) and field samples (n = 241), and negative oral fluid 
samples (n = 367) from experimentally inoculated pigs (n = 84) and field samples (n = 283).  
ROC analysis estimated the diagnostic sensitivity and specificity of the assay as 94.7%  (95% 
CI: 92.4, 96.5) and 100% (95% CI: 99.0, 100.0), respectively, at a sample:positive (S/P) ratio 
cutoff of  ≥ 0.40.  The results of this study suggest that the IgG oral fluid ELISA can provide 
efficient, cost-effective PRRSV monitoring in commercial herds and PRRSV surveillance in 
elimination programs. 
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INTRODUCTION 
"Oral fluid," the liquid collected by placing an absorptive device in the mouth3 is a 
combination of serum transudate and saliva.  Serum transudate enters the mouth from 
capillaries in the oral mucosa, crevicular gap, and gingival tissues.5,9  In humans, the ease of 
collecting oral fluid samples has facilitated the implementation of this approach for large 
epidemiological studies.  For example, in England, oral fluid samples were collected from 
11,698 children at home by their parents and mailed to the laboratory for antibody testing.4 
 
Oral fluid specimens are used in human medicine and forensics for the diagnosis or detection 
of a variety of infectious agents,24 hormones,20 and drugs.8  In particular, the recognition that 
both human immunodeficiency virus (HIV) and anti-HIV antibodies were present in oral 
fluid specimens2,12 stimulated assay development.  At present, surveillance and monitoring 
for HIV is commonly done by testing oral fluid specimens using rapid (20 minute) point-of-
care assays.26   
 
Although oral fluid testing has not been widely applied to livestock health and wellness 
management, veterinary literature on the presence of antibodies, pathogens, and acute phase 
proteins in oral fluids from animals reflects the findings in humans.31  In swine, infectious 
agents, cortisol, acute phase proteins, and progesterone have all been detected in oral fluid 
specimens under experimental and field conditions.13,25,28-30  Increasingly, oral fluid samples 
are used for the surveillance of porcine reproductive and respiratory syndrome virus 
(PRRSV) infections in commercial swine operations using polymerase chain reaction (PCR)-
based assays.7,15  While PCR-based assays are useful for detecting the circulation of PRRSV, 
antibody-based assays are informative regarding herd immunity and history of prior 
infection.  Therefore, the purpose of the present study was to evaluate the diagnostic 
performance of a commercial serum antibody ELISAa modified to detect anti-PRRSV 
antibodies in oral fluids.   
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MATERIALS AND METHODS 
Experimental design 
Oral fluid samples (n = 11) of known PRRSV status (“reference standards”) were prepared 
for use in optimizing the antibody isotype-specific PRRSV ELISAs (IgM, IgA, IgG) and as 
in-house plate controls.  Thereafter, experimental and field samples of defined status were 
used to describe antibody kinetics (IgM, IgA, IgG) and estimate the diagnostic performance 
(sensitivity and specificity) of the PRRSV IgG indirect ELISA. 
 
Oral fluid specimens 
Animals and animal care          All procedures for pigs intentionally inoculated with PRRSV 
or vaccinated with licensed modified live virus (MLV) PRRS vaccine were approved by the 
Institutional Animal Care and Use Committees (IACUC) at Iowa State University (IACUC 
#10-10-7033-S) and Kansas State University (IACUC #4567).  In all cases, oral fluid 
specimens were collected by allowing pigs access to a short length of cotton rope suspended 
in the pen.  After 20 to 30 minutes of pig interaction (biting) with the rope, oral fluid was 
extracted by passing the rope through a hand-operated wringer.b  These procedures are fully 
described elsewhere.1 
 
Reference standards          In brief, 5-week-old pigs (n ~1,100) in one PRRSV-negative, 
commercial wean-to-finish barn were intramuscularly vaccinated with 2 ml of a type 2 PRRS 
MLV vaccine.c  Oral fluid was collected from every pen (n = 37) in the barn at 0, 10, 15, 20, 
28, 35, 41, 49, 56, 75, and 91 days post vaccination (DPV).  At each collection, the oral 
fluids were pooled in a single 10 liter container.  In the laboratory, the fluid was clarified by 
centrifugation at 12,000 x g for 8 hours at 4°C and stored (-20°C) in 500 ml volumes.  After 
the entire volume had been processed, the oral fluid was placed in a single 10 liter container, 
stirred at 600 rpm for 30 min to assure homogeneity, decanted into 50 ml centrifuge tubes,d 
and stored at -80°C. 
 
Experimental samples          Oral fluid samples (n = 693) were collected from pigs inoculated 
with a type 2 PRRSV (NVSL 97-7895, GenBank® accession number AY545985) under 
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experimental conditions at the Kansas State University BL-2 animal facility.  Prior to 
PRRSV inoculation, pigs were confirmed free of PRRSV infection by testing serum samples 
using a commercial semi-quantitative real-time reverse transcription polymerase chain 
reaction (qRT-PCR) kite and a commercial ELISA,a respectively.  In each of 7 trials, 
approximately 200, 2- to 3-week old pigs (15 or 16 pigs per pen), were challenged with 1 x 
105 TCID50 of PRRSV.  One-half of the 3 ml challenge dose was administered 
intramuscularly and the remainder given intranasally.  Thereafter, oral fluid samples were 
collected at 0, 5, 7, 9, 11, 14, 17, and 21 day post inoculation (DPI) and stored at -80º C. 
 
Field samples          Expected PRRSV antibody-negative oral fluid field samples (n = 283) 
for assessing IgG ELISA specificity were selected from samples submitted to the Iowa State 
University Veterinary Diagnostic Laboratory (ISU VDL, Ames, Iowa USA) for PRRSV 
qRT-PCR testing from herds actively monitored for freedom from PRRSV infection.   
 
Potential PRRSV antibody-positive oral fluid samples were collected from wean-to-finish 
barns on 10 sites in a longitudinal field study32 (n = 600).  The ten sites were sourced from 
five sow sources located in four different states (Colorado, Illinois, Oklahoma, and Utah).  
Most sites (2 to 4 barns per site) were managed all-in all-out and the site fill time was one or 
two days.  Pigs were not vaccinated against PRRSV.  At each site, oral fluid samples were 
collected from the same 6 pens housing approximately 25 pigs per pen at 2-week intervals 
from placement (~ 3 weeks of age) to slaughter.  Following the completion of sample 
collection, the 600 oral fluid samples (6 pens x 10 barns x 10 sampling points) were 
randomly ordered and tested by qRT-PCR for PRRSV.  Expected PRRSV antibody-positive 
oral fluid field samples for assessing IgG ELISA sensitivity were defined as all samples 
collected from a pen after its first PRRSV qRT-PCR positive sample.  Among the 600 field 
samples screened, 241 samples met this definition. 
 
Protocol for PRRSV oral fluid IgG ELISA 
The procedure for the commercial indirect ELISAa was modified to detect anti-PRRSV 
antibody in porcine oral fluid specimens.16  The modified assay required 2 days to complete.  
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In brief, on day one, oral fluid samples were diluted 1:2 in dilution plates (150µl oral fluid 
sample + 150µl diluent) using the diluent provided with the test kit.  Diluted oral fluid was 
then transferred to the 96-well PRRSV antigen-coated plates (250 µl per well per sample).  
Negative and positive kit controls were diluted 1:30 using the kit diluent (10µl kit control + 
290µl diluent) and 100µl transferred to the assigned wells on the plates, i.e., A1 and B1 for 
negative controls; C1 and D1 for positive controls.  Thereafter, plates were incubated for 16 
hrs at 4°C in a refrigerated incubator.   
 
At the end of the 16 hr incubation period, the coated plates were washed three times with 
400μl of 1X kit wash solution.  To detect bound antibody, reagents were brought to room 
temperature and then 100 μl of a solution containing appropriately diluted horseradish 
peroxidase (HRP)-conjugated anti-swine IgGFC secondary antibodyf was added to each well 
and incubated for 30 min at 22°C.  Thereafter, plates were washed 3 times with wash 
solution, 100 µl of TMB enzyme substrate solution was added to each well, and the plates 
incubated at 22°C for 15 min.  After 15 min, 100 µl of kit stop solution was added to each 
well.  The plates were read at 650 nm using an ELISA plate readerg controlled by 
commercial software.h  The reactions were measured as optical density (OD) and then 
converted to sample-to-positive ratios (S/P) using the following formula: 
 
Equation 1.     S/P = ((Sample A(650) – NC x ))/((PC x – NC x ))   
 
In Equation 1, NC x  and PC x  represented the mean OD of the negative control wells and 
positive control wells, respectively.  For the PRRSV oral fluid IgG ELISA results to be valid, 
the mean of the kit positive control OD minus the mean of the kit negative control OD had to 
be ≥ 0.150 and the kit negative control mean OD ≤ 0.150.  These validity checks were 
identical to those required by the manufacturer for the PRRSV serum ELISA.   
 
Preparation of anti-swine IgGFC secondary antibody  
The appropriate dilution of horseradish peroxidase (HRP)-conjugated anti-swine IgGFC 
antibodyf was calculated for each ELISA kit lot to standardize the strength of the reaction 
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and assure the repeatability of results.  This was achieved by determining the dilution of anti-
swine IgGFC that matched the positive control OD value listed in the manufacturer’s 
Certificate of Analysis for the ELISA kit lot.  Certificates of Analysis for specific kit lots can 
currently be obtained using the manufacturers’ Certificate of Analysis Request Form 
[http://www.idexx.com/view/xhtml/en_us/livestock-poultry/certificates-of-analysis.jsf]. 
 
In brief, 4 dilutions (1:1000, 1:1500, 1:2000, 1:2500) of anti-swine IgGFC antibodyf were 
prepared using the anti-pig IgG:HRPO conjugate provided with the ELISAa kit as diluent and 
then stirred for 48 hours at 4°C.  To test the reactivity of the 4 dilutions of anti-swine IgGFC, 
kit negative and positive controls were diluted 1:30 (10 µl kit control + 290 µl kit sample 
diluent) and then 100 µl of diluted negative control was transferred into 48 wells, i.e., one-
half of the plate, and 100 µl of diluted positive control in each of the remaining 48 wells.  
Thereafter, the protocol for the PRRSV oral fluid IgG ELISA was conducted, as described 
above.  Negative control OD values were used to detect non-specific reactions.  Positive 
control OD values were used to determine the correct dilution of secondary antibody in two 
steps:  (1) Linear regression (Equation 2) was used to determine the equation of the line that 
described the relationship between positive control OD response and secondary antibody 
dilution (1:1000, 1:1500, 1:2000, 1:2500).   (2) The appropriate dilution of conjugated 
antibody dilution was calculated by substituting the mean positive control OD from the 
Certificate of Analysis for “x” into Equation 2 and then solving for “y”. 
 
Equation 2.  y	=	ax	+	c		
 
In Equation 2, “y” is optical density, “a” is the slope of the line, “x” is the dilution of 
secondary antibody, and “c” is the intercept.   
 
IgM and IgA protocols 
The commercial indirect ELISA was also modified to detect PRRSV-specific IgM (or IgA) 
antibody responses.  To detect bound antibody, HRP-conjugated anti-pig IgM antibodyi or 
anti-pig IgA antibodyj was diluted 1:2000 in conjugate diluent provided by the kit 
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manufacturer.  The Reference Standard oral fluid sample collected on day 0 was used as the 
negative control.  S/P values for IgM and IgA ELISAs were calculated as described in 
Equation 1 using Reference Standard samples collected on DPV 10 and 35 used as positive 
controls for the IgM and IgA ELISAs, respectively.   
 
For the PRRSV oral fluid IgM and IgA ELISA results to be valid, the mean of the kit 
positive control OD minus the mean of the kit negative control OD had to be ≥ 0.150 and the 
kit negative control mean OD ≤ 0.150.  These validity checks were identical to those required 
by the manufacturer for the PRRSV serum ELISA.   
 
Evaluation of IgG ELISA performance 
Receiver operator characteristic (ROC) curve analyses were performed using MedCalc® 
9.2.1.0.k  Diagnostic sensitivity, specificity and 95% confidence intervals were estimated for 
a range of S/P values (≥0.20 to ≥0.40) using test results from samples of defined status.  
Positive samples for estimating diagnostic sensitivity included oral fluid specimens from 
experimentally inoculated pigs (n = 251) collected on DPI 14, 17, and 21 and field samples 
(n = 241) collected from pens following their first PRRSV qRT-PCR positive oral fluid 
sample.  Negative samples for estimating diagnostic specificity included oral fluid specimens 
from experimentally inoculated pigs collected on DPI 0 (n = 84) and negative field samples 
(n = 283).  Negative oral fluid field samples were diagnostic samples submitted to the ISU 
VDL for PRRSV qRT-PCR testing from PRRSV-negative herds with active monitoring 
programs.   
 
RESULTS 
Reference standards         Anti-PRRSV antibody isotype (IgM, IgA, IgG) kinetics in 
reference standard samples are given in Figure 1 for oral fluid samples collected on DPV 0, 
10, 15, 20, 28, 35, 41, 49, 56, 75, and 91.  On DPV 10, S/P ratios for IgM, IgA, and IgG were 
1.00, 0.31, and 1.22, respectively.  On DPV 15, S/P ratios peaked at 1.87, 1.53, and 4.29 for 
IgM, IgA, and IgG.   IgM declined rapidly, i.e., the S/P ratio was 0.10 at DPV 28.  For DPV 
20 to 41, IgA S/P ratios ranged from a low of 0.59 (DPV 41) to a high of 1.05 (DPV 28).  For 
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DPV 49 to 91, IgA S/P ratios ranged from a low of 0.33 (DPV 75) to a high of 0.53 (DPV 
91).  IgG S/P ratios declined relatively slowly and steadily after DPV 15, reaching a low of 
2.65 on DPV 75. 
 
Experimental samples    Anti-PRRSV antibody isotype (IgM, IgA, IgG) kinetics in 
experimental samples are shown in Figure 2 for oral fluid samples collected on DPI 0, 5, 7, 9, 
11, 14, 17, and 21.  Mean IgM, IgA, and IgG S/P ratios on DPI 7 were 1.14 (95% confidence 
interval (CI) 1.04, 1.24), 0.09 (95% CI 0.06, 0.12), and 0.59 (95% CI 0.50, 0.68), 
respectively.  The mean IgM S/P ratio peaked at DPI 9 (1.88, 95% CI 1.78, 1.97) and 
declined rapidly to a mean S/P of 0.10 (95% CI 0.09, 0.13) on DPI 21.  Mean IgA and IgG 
S/P ratios peaked at DPI 11 (1.41, 95% CI 1.29, 1.53) and DPI 14 (3.69, 95% CI 3.52, 3.85), 
respectively.  Mean IgA and IgG S/P ratios remained relatively constant until the end of 
study at DPI 21.    
 
Field samples          Among the 60 pens on 10 sites from which oral fluid samples were 
collected over time, 39 pens had one or more PRRSV qRT-PCR-positive oral fluid samples 
over the course of the 18 week observation period.  Expected PRRSV antibody-positive oral 
fluid field samples were defined as all samples collected from a pen after its first PRRSV 
qRT-PCR positive sample.  Based on this definition, 241 (40%) of 600 oral fluid samples 
were defined as expected antibody-positive field specimens.  Specifically, these samples 
were from samples collected 2 to 18 weeks following the first qRT-PCR-positive result 
(Table 1).     
 
Mean oral fluid IgM, IgA, and IgG S/P ratios at the time of the first detection of PRRSV by 
qRT-PCR were 0.14 (95% CI 0.05, 0.23), 0.23 (95% CI 0.08, 0.38), and 1.98 (95% CI 1.42, 
2.53), respectively (Table 1).  Peak IgM S/P ratios 0.20 (95% CI 0.07, 0.33) were observed 
two weeks after the first detection of PRRSV by qRT-PCR and declined thereafter.  IgA and 
IgG S/P ratios were relatively steady, but tended to increase over the course of the 
observation period, reaching a peak in samples collected 18 weeks after the first qRT-PCR 
positive sample (Figure 3).   
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IgG indirect ELISA diagnostic performance          Estimates of IgG indirect ELISA 
performance were based on samples of defined status.  Positive samples (n = 492) for 
estimating diagnostic sensitivity included samples collected on DPI 14, 17, and 21 (n = 251) 
from experimentally inoculated pigs and field samples (n = 241) collected from pens after the 
first PRRSV qRT-PCR positive result.  Negative samples (n = 367) for estimating diagnostic 
specificity included oral fluid specimens from experimentally inoculated pigs collected on 
DPI 0 (n = 84) and field samples (n = 283) submitted to the ISU VDL for PRRSV qRT-PCR 
testing from PRRSV-negative monitored herds.  The cumulative S/P results for defined 
positive and negative oral fluid samples are given in Figure 4.  Mean S/P ratios of negative 
and positive samples were -0.001 (95% CI -0.006, 0.002) and 2.751 (95% CI 2.639, 2.864), 
respectively.  Estimates of diagnostic sensitivity and specificity by S/P ratio cutoff obtained 
through ROC analysis are shown in Table 2 and Figure 5.  
 
DISCUSSION 
In this study, the detection of anti-PRRSV antibodies in oral fluid specimens was evaluated 
using a commercial PRRSV indirect ELISAa performed using a procedure adapted to the oral 
fluid matrix.  The validity of this approach was supported by prior evidence that pigs, like 
humans and other species, produce detectable levels of specific antibodies in oral fluid in 
response to infection with PRRSV, as well as other pathogens.31  Essentially, the ELISA 
procedure was modified to calibrate the reactivity of the assay to the lower concentration of 
antibody present in oral fluid relative to serum.  Specific modifications included larger 
sample volume, less dilution of the sample, higher secondary antibody concentration, and 
longer sample incubation.16  A key step to creating a reproducible test was determining the 
kit lot-specific dilution of secondary antibody.  This was done by titrating the secondary 
antibody against a 1:30 dilution of positive and negative controls and then calculating the 
dilution of secondary antibody that matched the OD values for the positive and negative 
controls in the manufacturer’s Certificate of Analysis.  This step provided repeatable results 
and resulted in a cutoff in the oral fluid IgG ELISA that matched the cutoff recommended by 
the manufacturer for the serum ELISA (S/P ≥ 0.40).       
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Anti-PRRSV IgM, IgA, and IgG responses were evaluated in pen-based oral fluid samples 
using isotype-specific ELISAs.  IgM, IgA, and IgG were readily detected in populations in 
which the infection was synchronized among all individuals, i.e., reference standards and 
experimental samples.  However, this was not the case in field samples.  The reason for the 
difference in responses in synchronized vs. field samples is unknown, but it may be 
hypothesized that asynchrony in the spread of PRRSV infection in the field resulted in 
animals at different stages of the antibody response.  Consequently, IgM and IgA from pigs 
in the early stages of infection would have been diluted by oral fluid from animals not 
secreting those antibody isotypes.  In addition, IgG, both because of its higher concentration 
and its higher affinity, may have out-competed IgM and IgA for the antigenic sites available 
in the ELISA plate.19,23   
 
In contrast to IgM and IgA, IgG was readily detected at diagnostically useful levels in 
reference standards, experimental samples, and field samples for an extended period.  That is, 
IgG was consistently detected in reference standards through the termination of sample 
collection at 91 DPV, and in experimental samples and field samples throughout their 
respective observation periods, i.e., 21 and 126 days.   
 
Previous reports on anti-PRRSV serum antibody kinetics using indirect immunofluorescence 
assay (IFA) reported that IgM was first detected 5 to 7 DPI14,21,27 and IgG was detected 9 to 
11 DPI.35,21  Thus, the kinetics of serum IgM and IgG responses reported in the literature and 
the findings of this study for oral fluid were similar.  In contrast, IgA was first detected by 
immunoperoxidase monolayer assay (IPMA) in serum at 14 DPI, reached its maximum 
concentration at 25 DPI, and was undetectable after 35 DPI.18  That is, the reported detection 
of IgA in serum was later and shorter compared to the response observed in oral fluid.  
Overall, the observations for oral fluid are in agreement with our general understanding of 
antibody kinetics in serum and on mucosal surfaces.  Likewise, these data are compatible 
with previous reports that IgA is locally produced by serum-derived plasma cells in salivary 
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glands and duct associated lymphoid tissue (DALT), whereas IgM and IgG are primarily 
derived from serum, with some contribution from local production.31   
 
The use of pen-based oral fluid specimens, an unusual sample for an antibody ELISA, 
requires comment because an understanding of the epidemiological and statistical properties 
of the sample is central to the interpretation and analysis of the assay results.  In sampling 
terminology, an oral fluid sample is best described as a grab sample from a sample unit (pen), 
where “grab sample” is defined as a sample collected “at a specific point in time and at a 
specific location”17 and "sample unit" is the smallest division of the population and the level 
at which sample size calculations and random sampling procedures are performed.10,33-
34  Examples of sample units given by Toma et al.34 include, “an animal, a group of animals, 
i.e., a pen, a herd ….”  Oral fluid ELISA results are amenable to diagnostic interpretation 
because the pathogen-specific epidemic curve and immune responses of the individual pigs 
within the pen are highly correlated (dependent).  The link with specific time and place 
provides for the statistical analysis of the results, including analysis of geospatial 
relationships between pens in the context of the larger population.   
 
A pen-based sample should not be confused with a pooled sample.  More universally known 
as a “composite sample”,11 a pooled sample is created by combining two or more sample unit 
specimens into one aliquot for testing, thereby losing sample unit identity in the process,5  
Pooled samples are typically used to screen populations at a lower cost than testing 
individual samples using a 2-step process termed the “Dorfman procedure”.22  A pooled 
sample could be roughly equivalent to pen-based samples if the sample units were members 
of the same pen, but this is rarely the case.  In fact, the geospatial relationships among sample 
units in pooled samples are usually unknown.  Thus, testing of pooled samples may 
determine whether the defined analyte is present, but further statistical analyses or 
epidemiological interpretations are usually limited or impossible because of the loss of 
sample unit identification.  This study did not evaluate whether the ELISA procedure 
described could be used for pooled samples.  At any rate, given the ease of collecting pen-
based samples and the economic utility of ELISA-based testing, it is doubtful that testing 
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pooled oral fluid samples could be justified by the loss of statistical and epidemiological 
interpretability.   
 
Cumulatively, this study showed that a commercial serum antibody ELISAa adapted to oral 
fluid specimens can be used to detect anti-PRRSV antibody.  Testing for PRRSV antibody 
using pen-based oral fluids could provide an efficient, cost-effective approach for monitoring 
maternal antibody, vaccination compliance, and herd immune parameters in commercial 
herds and surveiling PRRSV infections in elimination programs.  The successful adaptation 
of one commercial serum antibody ELISA to the oral fluid matrix suggests that antibody 
assays for other pathogens could also be modified to this purpose.   
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d. Becton, Dickinson and Company, Bedford, MA. 
e. Applied Biosystems, Inc., Foster City, CA. 
f. Pig IgG-Fc Antibody (Cat No. A100-104P), Bethyl Laboratories, Inc., Montgomery, TX. 
g. EL800 micro plate reader, Bio Tek® Instruments Inc., Winooski, VT. 
h. GEN5™, Bio Tek® Instruments Inc., Winooski, VT. 
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Table 1.   Detection of PRRSV infection by qRT-PCR and ELISAs (IgM, IgA, IgG) in oral fluid specimens collected over 
time in 10 wean-to-finish barns on 10 sites 
 
Week* No. Pens†  
No. of PRRSV 
qRT-PCR 
positive pens 
Mean IgM S/P 
Ratio (95% CI) 
Mean IgA S/P 
Ratio (95% CI) 
Mean IgG S/P 
Ratio (95% CI) 
IgG-positive 
pens‡ 
0 39 39 (100%) 0.14 (0.05, 0.23) 0.23 (0.08, 0.38) 1.98 (1.42, 2.53) 27 (69%) 
2 37 15 (41%) 0.20 (0.07, 0.33) 0.28 (0.15, 0.42) 1.68 (1.40, 1.96) 37 (100%) 
4 35 7 (20%) 0.04 (-0.03, 0.10) 0.38 (0.22, 0.55) 1.53 (1.24, 1.82) 30 (86%) 
6 34 4 (12%) -0.02 (-0.02, -0.01) 0.49 (0.31, 0.67) 1.92 (1.58, 2.56) 31 (91%) 
8 27 0 (0%) -0.02 (-0.03, -0.01) 0.36 (0.18, 0.55) 1.50 (1.16, 1.85) 23 (85%) 
10 27 1 (4%) -0.02 (-0.02, -0.01) 0.51 (0.32, 0.69) 1.83 (1.45, 2.18) 24 (89%) 
12 27 1 (4%) -0.02 (-0.03, -0.01) 0.64 (0.38, 0.89) 1.55 (1.13, 1.97) 23 (85%) 
14 22 2 (9%) -0.01 (-0.02, -0.01) 0.53 (0.24, 0.81) 1.97 (1.47, 2.48) 20 (91%) 
16 18 1 (6%) 0.02 (-0.06, 0.11) 0.64 (0.29, 1.00) 2.28 (1.61, 2.93) 15 (83%) 
18 14 2 (14%) 0.02 (-0.03, 0.06) 0.80 (0.43, 1.17) 2.51 (2.01, 3.02) 14 (100%) 
 
* Week 0 was defined as the first PRRSV qRT-PCR positive oral fluid sample from a pen.  For any pen, the first qRT-PCR 
positive result may have occurred at any point in the 18-week observation period.  Subsequent weeks represent the designated 
time interval from the first qRT-PCR positive result. 
† Number of pens sampled at the designated time interval (weeks) following the first PRRSV qRT-PCR positive oral fluid sample. 
‡ IgG positive defined as HerdChek* PRRS X3 oral fluid IgG ELISA S/P ≥ 0.4 
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Table 2.  Diagnostic performance of an ELISA* performed using a protocol modified to 
detect anti-PRRSV antibodies in swine oral fluids 
 
 
* HerdChek® PRRS X3 Antibody Test Kit, IDEXX Laboratories, Inc., Westbrook, Maine USA 
  
S/P Ratio Sensitivity (%)              (95% confidence interval) 
Specificity (%)              
(95% confidence interval) 
≥ 0.20 95.3 (93.1, 97.0) 99.2 (97.6, 99.8) 
≥ 0.25 95.3 (93.1, 97.0) 99.5 (98.0, 99.9) 
≥ 0.30 95.3 (93.1, 97.0) 99.7 (98.5, 100.0) 
≥ 0.35 95.1 (92.9, 96.9) 100.0 (99.0, 100.0) 
≥ 0.40 94.7 (92.4, 96.5) 100.0 (99.0, 100.0) 
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Figure 1.   Kinetics of anti-PRRSV antibody isotypes (IgM, IgA, IgG) in reference standard 
samples 
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Figure 2.  Kinetics of anti-PRRSV antibody isotypes (IgM, IgA, IgG) in experimental 
samples 
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Figure 3.  Kinetics of anti-PRRSV antibody isotypes (IgM, IgA, IgG) in field samples where 
week zero (0) represents the first PRRSV PCR-positive sample from a pen 
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Figure 4.  Distribution of PRRSV IgG ELISA results by sample classification (negative, 
positive) relative to the assay cutoff (S/P ratio = 0.4). 
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Figure 5.  Estimates of PRRSV IgG ELISA diagnostic sensitivity and specificity by S/P 
ratio cutoff  
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ABSTRACT 
The precision of a Porcine reproductive and respiratory syndrome virus (PRRSV) oral fluid 
antibody enzyme-linked immunosorbent assay (ELISA) was evaluated by calculating reliability 
coefficients for assay repeatability (within laboratory) and assay reproducibility (between 
laboratories).  Randomly ordered oral fluid samples of known (n = 39) and unknown (n = 224) 
PRRSV antibody status were tested in 12 diagnostic laboratories.  Each laboratory tested the 
samples twice, first using an antibody ELISA kit and reagents provided to them (Phase 1) and 
then using an ELISA kit and reagents configured in their laboratory (Phase 2).  Repeatability 
(within laboratory) reliability coefficients calculated using results from samples of known 
PRRSV antibody status ranged from 0.724 to 0.997 in Phase 1 and 0.953 to 0.998 in Phase 2.  
Reproducibility (between laboratories) reliability coefficients were calculated for three 
conditions: Case 1 - samples of unknown status (n = 224); Case 2 - samples of known status (n = 
39), and Case 3 - all samples (n = 263).  Among the three cases, reliability coefficients ranged 
from 0.937 to 0.964 in Phase 1 and 0.922 to 0.935 in Phase 2.  For Case 3, it was estimated that 
96.67% of the total variation in Phase 1 and 93.21% in Phase 2 could be attributed to the oral 
fluid samples themselves.  Overall, the PRRSV oral fluid antibody ELISA was highly repeatable 
and reproducible.  This study supports the routine use of this test in laboratories providing 
diagnostic service to pig producers. 
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INTRODUCTION 
Oral fluid samples are increasingly used for the surveillance of pathogens in commercial swine 
operations in North America.  For example, the specimen type "swine oral fluid" was entered 
into the Iowa State University Veterinary Diagnostic Laboratory (ISU VDL) information 
management system in February, 2010.  During the remainder of 2010, 10,329 oral fluid 
specimens were received for testing.  This number increased to 32,544 in 2011.  In the first 3 
months of 2012, the ISU VDL received 13,226 oral fluid samples.  Thus, if the current level of 
submissions is maintained, the laboratory will receive >52,000 oral fluid samples in 2012.  The 
majority of oral fluid samples received at the ISU VDL are tested by PCR-based assays for 
PRRSV,4,8-9 influenza virus,1,10 porcine circovirus type 2,7 and other respiratory pathogens.   
 
Recently, the first antibody assay for oral fluids became available.5 Although oral fluid antibody 
assays are already widely available in human diagnostic medicine for a variety of pathogens,6 
this is the first application in swine diagnostic medicine.  Therefore, the objective of this study 
was to evaluate the repeatability and reproducibility of the PRRSV oral fluid ELISAa among 12 
laboratories that offer diagnostic services to swine producers and veterinarians. 
  
MATERIALS AND METHODS 
Experimental design 
Oral fluid samples (n = 263) were completely randomized and then distributed to the 12 
laboratories participating in the ring trial.  All participating laboratories had prior experience 
with ELISAs and three had previous experience with the PRRSV oral fluid ELISA.  Each 
laboratory received one set of samples, one "pre-configured" commercial PRRSV ELISA kita 
with pre-diluted reagents and controls, and a copy of the standard operating procedure for 
performing the assay.3  Each laboratory tested the samples on the kit provided (Phase 1) and then 
repeated the testing on a PRRSV ELISA kita configured in their laboratory (Phase 2).  Results 
were evaluated for test repeatability (within laboratory) and reproducibility (between 
laboratories). 
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Oral fluid specimens 
Oral fluid specimens tested (n = 263) included samples of unknown (n = 224) and known (n = 
39) PRRSV antibody status.  Oral fluid field specimens of unknown PRRSV antibody status 
samples were collected over a 2-month period from among diagnostic samples submitted to the 
Iowa State University Veterinary Diagnostic Laboratory (ISU VDL) for either PRRSV real-time 
reverse-transcription polymerase chain reaction (rRT-PCR) or PRRSV antibody testing.  ISU 
VDL records indicated that specimens were collected on 42 different production sites located in 
7 states (Colorado, Iowa, Illinois, Indiana, Missouri, North Carolina, and Ohio).  Samples were 
included on the basis of sufficient sample volume and without knowledge of testing results in the 
ISU VDL.  Each sample was assigned a random number, divided into 12 aliquots of 1.25 ml, and 
stored at – 20 ̊ C.   
 
Oral fluid samples of known PRRSV antibody status originated from pigs inoculated with a type 
2 PRRSV modified-live virus vaccineb and collected on 0, 10, 15, 20, 28, 35, 41, 49, 56, 75, and 
91 days post vaccination (DPV).  These samples were used to create 13 samples that were run on 
every plate.  Specifically, the day 0 sample was used as in-house negative control; the day 75 
sample was used to create high (1:5), medium (1:10), and low (1:20) positive controls using the 
PRRS ELISA kita sample diluent.  The remaining 9 samples, i.e., DPV 10, 15, 20, 28, 35, 41, 49, 
56, 91, were split into 3 aliquots and then placed within the sample set such that all 9 were run on 
every plate. 
 
Oral fluid ELISA procedures 
Oral fluid samples were tested on a commercial PRRSV ELISA using a protocol designed to 
detect PRRSV antibody in oral fluid.3,5  In Phase 1, all 12 laboratories used the same kit lot 
(40959–W721).  The 11 laboratories that participated in Phase 2 used 5 different kit lots: 5 used 
lot 40959–EG288, 3 used lot 40959–EG233, and 1 laboratory each used lots 40949–W721, 
40949–W791, and 40949–X861. Phase 1 and Phase 2 were completed before the data were 
analyzed.  
 
To perform the test, oral fluid samples were diluted 1:2 in dilution plates using the diluent 
provided with the test kit.  250 µl of diluted oral fluid was then transferred to the 96-well PRRSV 
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antigen-coated plates.  Negative and positive kit controls were diluted 1:30 using the kit diluent 
and 100 µl transferred to the assigned wells on the plates (i.e., A1 and B1 for negative controls; 
C1 and D1 for positive controls).  Thereafter, plates were incubated for 16 hr at 4°C.  Three 
laboratories used refrigerated incubators; all other laboratories used standard refrigerators.  At 
the end of the 16 hr incubation period, the plates were washed 3 times with 400 μl of 1˟ kit wash 
solution.  To detect bound antibody, reagents were brought to room temperature and then 100 μl 
of a solution containing appropriately diluted horseradish peroxidase (HRP)–conjugated anti-
swine immunoglobulin G (IgGFC) secondary antibodyc was added to each well and incubated for 
30 min at 22°C.  Thereafter, plates were washed 3 times with wash solution, 100 µl of 
tetramethylbenzidine enzyme substrate solution was added to each well, and the plates incubated 
at 22°C for 15 min.  After 15 min, 100 µl of kit stop solution was added to each well.  The plates 
were read at 650 nm and measured as optical density (OD).   
 
All laboratories provided results as both OD and sample-to-positive (S/P) ratios.  S/P was 
calculated as: 
 
S/P ൌ ሾୗୟ୫୮୪ୣ	୅ሺ଺ହ଴ሻି୒େሿ	ሺ୔େି୒େሻ  (1) 
 
where NC and PC represented the mean OD of the two negative control wells and two positive 
control wells, respectively.  S/P ratios ≥ 0.40 were considered positive for PRRSV antibody 
(Kittawornrat et al., 2012).   
 
Statistical analysis 
The consistency of the PRRSV oral fluid ELISA was quantified by estimating reliability 
coefficients (ρ) for assay repeatability (within laboratory) and assay reproducibility (between 
laboratories) using the results from oral fluid samples of known (n = 39) and unknown (n = 224) 
PRRSV antibody status, respectively.2,10   
 
For calculation of repeatability reliability coefficients, the model and associated parameters were 
based on n samples with d repeated measurements of a continuous variable x and denoted by xij, 
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the jth measurement made on the ith subject (for i = 1, … , n and j = 1,…, d):   
 
ݔ௜௝ ൌ 	 ߬௜ ൅	ߚ௝ ൅	݁௜௝    (2) 
 
where τi is the sample effect, βj is the plate effect, and eij is the measurement error.  For within 
laboratory data, the d repeated measurements referred to results derived from repeated testing of 
the same samples by the same laboratory, i.e., the 13 samples tested on every plate.  The 
equation for calculating assay repeatability reliability coefficients is given as:  
 
ߩ	 ൌ 	 ఙഓమఙഓమା	ఙഁమା	ఙ೐మ   (3) 
 
where ߪఛଶ is the variance due to the oral fluid sample, ߪఉଶ is the variance due to the plate, and ߪ௘ଶ 
is the variance due to measurement error.   
 
Reproducibility reliability coefficients were estimated for three conditions (Case 1: samples of 
unknown status, Case 2: samples of known status, and Case 3: all oral fluid samples) using 
equation 4:  
 
ݔ௜௝௞ ൌ 	 ߬௜ ൅	ߙ௞ ൅	ߛ௝௞ ൅	߱௜௞ ൅	݁௜௝௞ (4) 
 
In equation 4, ݔ௜௝௞ is the measurement made on the ith subject in jth kit lot number by kth 
laboratory (for i = 1, … , n, j = 1,…, d, and k = 1, …, m), ߬௜ is the effect of the ith oral fluid, ߙ௞ 
is the effect of the kth laboratory, ߛ௝௞is the effect of kit lot number jth within laboratory k (where 
kit lot is nested within laboratory), ߱௜௞ is the interaction between oral fluid i and laboratory k and 
݁௜௝௞ is the measurement error.  The reproducibility reliability coefficient may be calculated as: 
 
ߩ	 ൌ 	 ఙഓమఙഓమା		ఙഀమା	ఙംమା	ఙഘమା	ఙ೐మ (5) 
 
where the variance ߪఛଶ	 is nominator and the total variance components, i.e., sum of variances of 
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subject error, laboratory error, kit lot error, the interaction between oral fluid and laboratory and 
measurement error (denominator).   
 
Variance estimates for equations 2 and 4 were calculated from random effect models solved 
using commercial statistical software.d  S/P ratios within linear random effects models were 
analyzed using the GLIMMIX procedure.  Oral fluid samples, laboratory, kit lot number, and 
interaction between oral fluid and laboratory were treated as random effects.  
 
RESULTS 
A total of 3,156 PRRSV oral fluid ELISA results were produced by the 12 laboratories that 
participated in Phase 1 (Figure 1).  Among these 1,581 (50.1%) were positive at a S/P cutoff of 
≥0.40.  In Phase 2 (Figure 2), the 11 participating laboratories produced 2,885 results with 1,438 
positives.  As illustrated in Figures 1 and 2, the dispersion of the results increased as the 
magnitude of the S/P response increased.  The number of samples tested, mean ELISA S/P 
ratios, and S/P standard deviation are shown in Table 1 by laboratory.  Among the samples of 
unknown PRRSV antibody status (n = 224), discordant results were produced in 7 samples in 
Phase 1 and 5 samples in Phase 2 (Table 2). 
 
Repeatability (within laboratory) reliability coefficients calculated from linear random effects 
models are shown in Table 3.  The within laboratory agreement ranged from 0.942 to 0.997 in 
Phase 1 and 0.953 to 0.998 in Phase 2.  Laboratory 6 reported one false positive result in Phase 
1, which resulted in a within laboratory reliability coefficient of 0.724 for that laboratory.  No 
statistically significant difference in repeatability was detected for any laboratory when 
comparing Phase 1 vs. Phase 2 reliability coefficients.  
 
Reproducibility (between laboratories) reliability coefficients were calculated using results from 
224 samples of unknown status and 39 samples of known status samples tested in all 
laboratories.  As shown in Table 3, this allowed for the calculation of reproducibility reliability 
coefficients for three conditions: Case 1 - samples of unknown status (n = 224); Case 2 - samples 
of known status (n = 39), and Case 3 - all samples (n = 263).  Table 4 lists the variance 
components estimates used to calculate the reproducibility reliability coefficients for Case 3, i.e., 
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oral fluid samples, laboratory, ELISA kit lot, ELISA plate, and measurement error.  Among 
these sources of variation, oral fluid samples accounted for 95.67% of the total variation in Phase 
1 and 93.21% in Phase 2.   
 
DISCUSSION 
A recent analysis of the PRRSV oral fluid ELISA reported test sensitivity of 94.7% (95% CI: 
92.4, 96.5) and specificity of 100% (95% CI: 99.0, 100.0).5 Further evaluation of this ELISA was 
motivated by the fact that the protocol differs significantly from the protocol for the PRRSV 
serum antibody ELISA.  That is, in contrast to the serum antibody assay, the PRRSV oral fluid 
ELISA uses a sample volume of 250 μl (100 μl for serum), a 16 hr incubation period at 4° C (30 
min at 22°C for serum), and requires the operator to purchase and correctly prepare the 
appropriate concentration of anti-swine IgGFC secondary antibody.3,5  To fully evaluate the 
precision of the assay, the study was conducted in a ring test involving various North American 
laboratories expected to offer this test to swine clientele on a routine basis.   
 
Visual analysis of the cumulative results (Figure 1) showed greater dispersion of S/P ratios in 
Phase 2, i.e., laboratories tested the samples on a total of 5 ELISA kit lots using reagents they 
had prepared, as compared with Phase 1, i.e., samples were tested on a single kit lot with pre-
diluted reagents.  However, as shown in Table 2, relatively few discordant qualitative results 
were seen either in Phase 1 (7 discordant samples) or Phase 2 (5 discordant samples).  With one 
exception, discordant results were single events.  The one exception was a sample (#193) which 
was reported positive in 3 of 12 laboratories in Phase 1 and 2 of 11 laboratories in Phase 2.  The 
frequency of discordant results for this sample can be explained by the fact its mean S/P value 
lies close to the positive cutoff (S/P ≥ 0.40).  Thus, small differences in quantitative 
measurements produced divergent categorical results. 
 
Reliability coefficients were used as quantitative summary measures of agreement.  By 
definition, the repeatability reliability coefficient is a measure of intra-laboratory assay 
agreement and the reproducibility reliability coefficient is a measure of inter-laboratory 
agreement.12 Shoukri and Pause11 have suggested that coefficients > 0.75 indicate excellent 
reliability.  The limitation of this approach is that reliability coefficients reflect both the assay 
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and the distribution of the analyte in the samples tested.  That is, given the same assay, reliability 
coefficient estimates will be affected as the concentration and/or prevalence of the analyte in the 
population of samples tested varies.2    
 
Repeatability reliability coefficients were calculated using 13 samples tested on each ELISA 
plate in every laboratory (Table 3).  Coefficients ranged from 0.724 to 0.997 (Phase 1) and 0.953 
to 0.998 (Phase 2).  No statistically significant differences were detected in Phase 1 vs. Phase 2 
repeatability reliability coefficients in the 11 laboratories participating in both phases.  Based on 
the reliability coefficient criteria described by Shoukri and Pause,11 the results were shown to be 
highly repeatable in the participating laboratories.   
 
Reproducibility reliability coefficients were calculated for three cases (Table 3):  samples of 
unknown PRRSV antibody status (Case 1, n = 224), samples of known status (Case 2, n = 39), 
and all samples tested in every laboratory, regardless of PRRSV antibody status (Case 3, n = 
263).  Among the three cases, reliability coefficients ranged from 0.937 to 0.964 in Phase 1 and 
0.922 to 0.935 in Phase 2, indicating excellent reproducibility across laboratories.11  Based on 
overall samples results, the variance components estimated that 95.7 % of the total variation in 
Phase 1 and 93.2 % in Phase 2 could be attributed to the oral fluid samples themselves (Table 4), 
with the remainder of the variation allocated to laboratory, ELISA kit lot, ELISA plate 
(laboratory), and measurement error.   
 
Cumulatively, the current study showed that a commercial serum antibody ELISA adapted to 
oral fluid samples was highly reproducible within and between laboratories responsible for swine 
health testing.  These results support the routine use of this test in laboratories providing 
diagnostic service to pig producers.  Thus, herd monitoring based on oral fluid antibody testing 
could be one part of a PRRSV control and/or elimination program.  The successful ring trial of 
one commercial serum antibody ELISA to the oral fluid diagnostic suggests that antibody assays 
for other pathogens could also be modified to this approach.  
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Table 1.  Summary of results used to estimate test variance components in the PRRSV oral fluid ELISA ring trial  
Lab No. of samples 
--------------  Phase 1 Test Results* --------------  --------------  Phase 2 Test Results† -------------- 
Mean S/P SD No. Positive‡ No. Negative‡ Mean S/P SD No. Positive‡ No. Negative‡ 
1 39
§ 2.47 0.58 36 3 2.51 0.57 36 3 
   224¦ 1.03 1.32 96 128 0.92 1.17 95 129 
2 39 2.86 0.61 36 3 2.34 0.59 36 3 
224 0.98 1.32 95 129 0.83 1.06 95 129 
3 39 2.53 0.63 36 3 3.10 0.66 36 3 
224 0.84 1.13 95 129 0.92 1.28 95 129 
4 39 2.99 0.59 36 3 3.10 0.55 36 3 
224 1.14 1.50 95 129 1.17 1.52 98 126 
5 39 3.07 0.58 36 3 2.68 0.60 33 2 
224 1.13 1.45 96 128 1.01 1.27 96 128 
6 39 2.96 0.66 37 2 Laboratory did not participate in Phase 2 testing 224 0.91 1.20 95 129 
7 39 2.65 0.61 36 3 2.39 0.54 36 3 
224 0.94 1.18 95 129 0.73 0.93 95 129 
8 39 2.74 0.64 36 3 2.52 0.62 36 3 
224 0.97 1.29 97 127 0.83 1.07 95 129 
9 39 2.69 0.61 36 3 2.37 0.56 33 2 
224 0.93 1.25 96 128 0.78 1.06 95 129 
10 39 2.49 0.60 36 3 2.19 0.66 36 3 
224 0.88 1.17 97 127 0.69 0.93 95 129 
11 39 2.84 0.68 36 3 2.32 0.68 36 3 
224 0.87 1.18 95 129 0.68 0.92 94 130 
12 39 2.54 0.60 36 3 2.33 0.65 36 3 224 0.87 1.11 96 128 0.77 1.03 95 129 
* Laboratories were provided PRRSV ELISA kit (same lot number) and all reagents needed to test the samples. 
† Laboratories provided their own PRRSV ELISA kit and prepared all reagents needed to test the samples.  Note: 4 known-status 
samples in laboratories 5 and 9 were of insufficient volume to test in Phase 2 
‡ Samples with S/P ≥ 0.40 were classified as positive (Kittawornrat et al., 2012) 
§ S/P ratios from samples with known PRRSV antibody status  
 ¦ S/P ratios from samples with unknown PRRSV antibody status  
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Table 2.  Summary of PRRSV oral fluid ELISA discordant results among 224 oral fluid samples of unknown PRRSV antibody 
status (S/P cutoff ≥ 0.40) 
Phase 
Sample 
random 
number 
Laboratories participating in the PRRSV oral fluid ELISA ring test (S/P ratios) 
1 2 3 4 5 6 7 8 9 10 11 12 
P
h
a
s
e
 
1
 
4 -0.05 -0.03 0.00 -0.02 0.02 0.00 0.02 -0.03 -0.02 0.01 -0.04 1.21 
16 0.05 -0.01 0.00 -0.01 0.01 0.04 0.04 0.03 0.00 0.72 0.00 0.01 
62 0.07 -0.04 -0.01 0.00 0.02 0.02 0.04 0.00 0.07 0.96 0.00 0.02 
112 -0.03 0.00 -0.02 -0.05 0.00 -0.08 0.03 0.51 -0.01 0.00 -0.06 -0.02
151 1.19 -0.03 -0.04 -0.06 0.00 -0.04 -0.01 0.08 -0.03 -0.02 -0.04 0.04 
175 -0.03 -0.01 -0.04 -0.05 0.00 -0.04 0.02 -0.01 3.03 -0.02 -0.02 0.00 
193 0.27 0.26 0.26 0.39 0.45 0.27 0.33 0.41 0.40 0.26 0.26 0.25 
P
h
a
s
e
 
2
 
2 0.98 0.86 0.68 1.60 1.07 NA 0.83 0.96 0.80 0.61 NA 0.31 
12 0.17 0.22 0.12 0.43 0.25 NA 0.20 0.19 0.14 0.14 0.12 0.15 
53 -0.03 0.00 -0.02 0.51 0.01 NA 0.00 0.01 -0.07 0.01 -0.01 0.00 
193 0.32 0.32 0.27 0.56 0.51 NA 0.30 0.28 0.30 0.17 0.20 0.22 
231 0.81 0.51 0.51 0.69 0.70 NA 0.43 0.47 0.62 0.53 0.33 0.48 
 
* PRRSV ELISA kit and all reagents required to test the samples were provided to each laboratory. 
† Laboratories provided their own PRRSV ELISA kit and prepared all reagents required to test the samples. 
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Table 3.  PRRSV oral fluid antibody ELISA reliability coefficients* 
 
* Repeatability reliability coefficients were calculated using the data from 13 samples 
tested on each plate in each laboratory.  Reproducibility reliability coefficients were 
calculated for 3 cases:  all samples (n = 263), field samples of unknown PRRSV 
antibody status (n = 224), and samples of known PRRSV antibody status (n = 39).  
Shouki and Pause (1999) interpret reliability coefficients as excellent (> 0.75), good 
(0.40 to 0.75), and poor (< 0.4). 
† PRRSV ELISA kit and all reagents required to test the samples were provided to each 
laboratory. 
‡ Laboratories provided their own PRRSV ELISA kit and prepared all reagents required 
to test the samples.  
 
 
Repeatability reliability coefficients  Phase 1† Phase 2‡ 
Laboratory 1 0.991 0.995 
Laboratory 2 0.986 0.989 
Laboratory 3 0.996 0.994 
Laboratory 4 0.967 0.986 
Laboratory 5 0.990 0.998 
Laboratory 6 0.724 (no results provided) 
Laboratory 7 0.942 0.953 
Laboratory 8 0.950 0.987 
Laboratory 9 0.994 0.967 
Laboratory 10 0.969 0.956 
Laboratory 11 0.997 0.997 
Laboratory 12 0.991 0.960 
Reproducibility reliability coefficients Phase 1† Phase 2‡ 
Case 1: samples of unknown status  0.964 0.935 
Case 2: samples of known status 0.937 0.922 
Case 3: all samples 0.957 0.932 
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Table 4.  Estimates of the variance components used to calculate reproducibility reliability coefficients for the PRRSV oral 
fluid antibody ELISA* 
 
* Variance components were estimated in a linear random effects model using the S/P data from all oral fluid samples (n = 263). 
† PRRSV ELISA kit and all reagents required to test the samples were provided to each laboratory. 
‡ Laboratories provided their own PRRSV ELISA kit and prepared all reagents required to test the samples. 
 
Variation by source 
Phase 1† Phase 2‡ 
Variance (95% CI) % of model variance Variance (95% CI) % of model variance 
Oral fluid sample 1.768 (1.494 – 2.126) 95.67 1.403 (1.185 – 1.688) 93.21 
Laboratory  0.007 (0.003 – 0.048) 0.39 0.022 (0.009 – 0.093) 1.43 
ELISA kit lot-to-lot  Does not apply because all laboratories used kits from the same lot 
0.007 (0.001 – 158.2) 0.60 
ELISA plate (laboratory)  0.010 (0.006 – 0.023) 0.54 0.003 (0.002 – 0.008) 0.21 
Measurement error 0.063 (0.060 – 0.066) 3.40 0.071 (0.067 – 0.075) 4.70 
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Figure 1.  Results from 224 samples tested in each of 12 laboratories.  All laboratories 
using the same PRRSV oral fluid antibody ELISA kit lot and reagents  
(Phase 1). 
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Figure 2.  Results from 224 samples tested in each of 11 laboratories on a total of 5 
PRRSV ELISA kit lots using reagents they had prepared (Phase 2). 
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CHAPTER 5.  KINETICS OF THE PORCINE REPRODUCTIVE AND 
RESPIRATORY SYNDROME VIRUS (PRRSV) HUMORAL IMMUNE RESPONSE 
IN SWINE SERUM AND ORAL FLUIDS COLLECTED FROM INDIVIDUAL 
BOARS 
 
Apisit Kittawornrat, Mark Engle, Yaowalak Panyasing, Chris Olsen, Kent Schwartz, Anna 
Rice, Sergio Lizano, Chong Wang, Jeffrey Zimmerman 
 
A paper accepted for publication in BMC Veterinary Research 
 
ABSTRACT 
Background: The object of this study was to describe and contrast the kinetics of the 
humoral response in serum and oral fluid specimens during acute porcine reproductive and 
respiratory syndrome virus (PRRSV) infection.  The study involved three trials of 24 boars 
each.  Boars were intramuscularly inoculated with a commercial modified live virus (MLV) 
vaccine (Trial 1), a Type 1 PRRSV field isolate (Trial 2), or a Type 2 PRRSV field isolate 
(Trial 3).  Oral fluid samples were collected from individual boars on day post inoculation 
(DPI) -7 and 0 to 21.  Serum samples were collected from all boars on DPI -7, 0, 7, 14, 21 
and from 4 randomly selected boars on DPI 3, 5, 10, and 17.  Thereafter, serum and oral fluid 
were assayed for PRRSV antibody using antibody isotype-specific ELISAs (IgM, IgA, IgG) 
adapted to serum or oral fluid.   
Results: Statistically significant differences in viral replication and antibody responses were 
observed among the three trials in both serum and oral fluid specimens.  PRRSV serum IgM, 
IgA, and IgG were first detected in samples collected on DPI 7, 10, and 10, respectively.  
Oral fluid IgM, IgA, and IgG were detected in samples collected between DPI 3 to 10, 7 to 
10, and 8 to 14, respectively.   
Conclusions: This study enhanced our knowledge of the PRRSV humoral immune response 
and provided a broader foundation for the development and application of oral fluid 
antibody-based diagnostics. 
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BACKGROUND 
The presence of systemic and locally-produced antibodies in oral fluid has led to its use as a 
diagnostic specimen for a variety of infectious diseases.  In humans, oral fluids have been 
used in the diagnosis of human immunodeficiency virus (HIV), Hepatitis A, B, and C 
viruses, measles, mumps and other infectious diseases [1].  In swine, antibodies against a 
variety of economically significant pathogens have been reported in oral fluids, including 
classical swine fever virus [2-3], porcine circovirus type 2 [4], porcine reproductive and 
respiratory syndrome virus [5-6], swine influenza virus [7], transmissible gastroenteritis virus 
[8], Actinobacillus pleuropneumoniae [9], and E. coli [10].  In large measure, the kinetics of 
the antibody response against individual agents has not been described.  Therefore, the 
purpose of present study was to describe and contrast the ontogeny of PRRSV IgM, IgA, and 
IgG in oral fluids and serum specimens collected from individually housed boars during 
acute PRRSV infection. 
 
RESULTS  
PRRSV antibody isotypes in serum 
The PRRSV antibody isotype (IgM, IgA, and IgG) responses in serum samples are shown in 
Figure 1 and Table 1.  Estimates for DPI -7, 0, 7, 14, 21 were based on data from 72 boars, 
whereas estimates for DPIs 3, 5, 10, and 17 were based on a subset of 12 animals randomly 
selected from the 72 boars.  Based on pairwise comparisons, statistically significant levels of 
IgM were detected by DPI 7, peaked at DPI 14, and remained stable through DPI 21.  In 
contrast, statistically significant levels of IgA and IgG were detected by DPI 10, after which 
they remained stable (IgA) or increased significantly (IgG) through DPI 21.  Further analysis 
showed that IgM and IgA responses were associated with DPI (IgM: p < 0.0001, IgA: p < 
0.0001), trial (IgM: p < 0.0001, IgA: p < 0.0149), and the interaction between trial and DPI 
(IgM: p < 0.0001, IgA: p < 0.0001).  In contrast, DPI (p < 0.0001) was the only factor 
associated with the IgG response.  Neither the age of the boar at the time of inoculation nor 
the quantity of oral fluid collected from each boar had a significant effect on IgM, IgA, or 
IgG. 
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PRRSV antibody isotype in oral fluid samples 
The PRRSV antibody isotype (IgM, IgA, and IgG) responses in oral fluid samples are shown 
in Figure 2 and Table 1 for oral fluid samples collected on DPI -7, 0-14, 17, and 21.  
Estimates were based on ≥66 oral fluid samples at each sampling point.  IgM S/P ratios were 
statistically significant on DPI 7, peaked at DPI 11, and declined thereafter.  Levels of IgA 
and IgG were significant on DPI 8 and increased thereafter through the end of the experiment 
(DPI 21).  Factors significantly associated with IgM and IgA S/P ratios included trial (IgM: p 
< 0.0001, IgA: p = 0.0273), DPI (IgM: p < 0.0001, IgA: p < 0.0001), oral fluid volume (IgM: 
p = 0.0002, IgA: p < 0.0001), and the interaction between trial and DPI (IgM: p < 0.0001, 
IgA: p < 0.0001).  Factors associated with IgG included DPI (p < 0.0001) and the interaction 
of trial by DPI (p < 0.0001).  Regardless of isotype, boar age at the time of inoculation had 
no significant effect on antibody response. 
 
Comparison of PRRSV antibody responses in serum and oral fluid 
A comparison of the qualitative antibody response in serum vs. oral fluid found no 
significant difference in the proportion of ELISA positive results on DPI 0 – 14, 17, and 21 
(Table 2).  No significant difference was detected in the number of positive results for each 
pair-wise sample combination (serum vs. oral fluid) by trial, DPI, or trial by DPI.  On DPI 
21, 100% of serum and oral fluid samples were positive with mean S/P ratios of 1.69 (95% 
Confidence Interval [CI]: 1.58, 1.79) and 2.60 (95% CI: 2.34, 2.86), respectively.  An 
analysis of the quantitative antibody isotype responses in serum and oral fluid samples using 
test results from samples collected on DPI -7, 0 – 14, 17, 21 estimated Pearson’s correlation 
coefficient as r = 0.84, 0.78, and 0.90 for IgM, IgA, and IgG responses, respectively (Figure 
3).   
 
Comparison between viremia levels and antibody responses  
All serum samples from DPI -7 and 0 (n = 144) were PRRSV qRT-PCR negative, whereas 
all serum samples from boars tested on DPI 3 (n = 12) and DPI 7 (n = 72) were positive.  
PRRSV was detected in oral fluids from 7 of 69 boars at DPI 1, 52 of 68 boars at DPI 2, 66 
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of 70 at DPI 3, and all boars were PRRSV qRT-PCR positive at DPI 4.  A comparison of 
matched samples from individual boars showed that oral fluid was equal to serum for the 
detection of PRRSV at DPI 7 and more likely to be positive than serum on DPI 14 and 21.  
These data are reported in detail elsewhere [11].   
 
To evaluate the association between viremia and antibody responses, cumulative serum and 
oral fluid PRRSV qRT-PCR (loge geq/µl) and antibody isotype (IgM, IgA, IgG) responses 
over time were re-expressed as area under the curve (AUC) (MedCalc®) prior to performing 
the analyses.  The mean qRT-PCR and antibody isotype AUCs for serum and oral fluid are 
given in Table 3.  Statistical analysis (ANOVA) of main effects showed significant 
differences among trials (p < 0.001), sample type (p < 0.001), and quantitative responses 
(PRRSV, IgM, IgA, IgG; p < 0.001).  With the exception of serum IgG, statistically 
significant differences in means were detected among trials both in the replication of 
PRRSVs and in antibody responses (Tukey’s Honestly Significant Difference (HSD) test).  
However, at the individual boar level, correlation analysis found a weak association between 
PRRSV viremia AUC and serum IgM, IgA, or IgG AUCs (r = 0.3762, 0.2915, and 0.0005).  
Likewise, the correlation was weak between PRRSV oral fluid AUC and oral fluid IgM, IgA, 
or IgG AUCs (r = 0.3147, 0.2671, and 0.2137).   
 
DISCUSSION 
By definition, oral fluid is a mixture of saliva, oral mucosal transudate, and gingival 
crevicular fluid recovered from the buccal cavity using an absorptive device [12].  Among a 
variety of other constituents, oral fluid contains both locally-derived and systemic antibodies 
[13].  Thus, pathogen-specific IgM, IgA, and IgG for PRRSV [5], influenza A virus [7], and 
porcine circovirus type 2 [4] could be detected in oral fluid samples collected from groups of 
pigs (pens) under either experimental or field conditions.  The largest proportion of locally 
produced antibody consists of dimeric secretory IgA (SIgA) produced by plasma cells in 
salivary glands and duct-associated lymphoid tissue (DALT) [14].  IgM and IgG are also 
produced in these tissues, but the majority of IgM and IgG in oral fluid is derived from serum 
via the gingival crevicular fluid [15].   
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In the present experiment, the collection of paired oral fluid and serum samples from 72 
individually-housed boars inoculated with three different PRRSV isolates allowed for a more 
comprehensive evaluation of the onset and magnitude of serum and oral fluid antibody 
isotype responses, as well as the variation therein.  Statistically significant differences in viral 
replication and antibody responses were observed among the three trials in both serum and 
oral fluid specimens (Table 3).  Since each trial included only one virus isolate, statistically 
valid comparisons of the effects of virus isolates on PRRSV replication and antibody 
responses were not possible.  Nevertheless, the statistically significant differences in virus 
replication and antibody response observed among trials was consistent with previous reports 
of virus isolate-dependent differences in the magnitude of replication in pigs [16] and 
corresponding differences in antibody response [16-17].  However, at the individual boar 
level, the correlation between virus replication and antibody response was relatively weak.  
Thus, what was true for the group of boars in a trial did not necessarily apply to an individual 
boar.  
 
The purpose of this study was to describe and contrast the kinetics of PRRSV antibody in 
oral fluids and serum.  PRRSV serum IgM, IgA, and IgG were first detected in samples 
collected on DPI 7, 10, and 10, respectively.  These results were compatible with prior 
reports describing the detection of PRRSV serum IgM between DPI 5 and 7 [18-20], IgG 
between DPI 9 and 11 [19, 21], and IgA at DPI 14 [19].  PRRSV oral fluid IgM, IgA, and 
IgG appeared concurrently with serum antibodies, but collection of daily oral fluid samples 
provided more precise estimates.  That is, oral fluid IgM, IgA, and IgG were detected in 
samples collected between DPI 3 to 10, 7 to 10, and 8 to 14, respectively.  There are no prior 
reports on PRRSV oral fluid antibody kinetics in individual animals with which to compare 
these results.  However, we previously reported the detection of PRRSV oral fluid IgM and 
IgG in pen-based oral fluid samples from experimentally inoculated animals on DPI 7 [5].  
Thus, the PRRSV serum and oral fluid antibody responses observed in this study were in 
agreement with prior observations on PRRSV and our general understanding of the humoral 
immune response as reflected in these sample matrices [14, 22].  Most significantly, this 
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study provided a broader foundation for understanding, developing, and interpreting oral 
fluid antibody-based diagnostics in the context of the humoral immune response.   
 
CONCLUSIONS 
This study demonstrated that anti-PRRSV antibody isotypes can be detected in oral fluid 
specimens.  These results were compatible with prior reports describing the detection of anti-
PRRSV antibody in both serum and oral fluid.  Detection of PRRSV antibody in oral fluids 
collected from individual boars could provide an effective approach for monitoring PRRSV 
infection in boar studs.  Successful oral fluid collection and testing from individual boars 
suggests that approach could also be applied to population in swine production systems, i.e. 
pen-housed sows, farrowing crates, etc.    
 
METHODS 
Experimental design           
A total of 72 boars ranging from 6 months to 3.6 years of age under the ownership of PIC 
North America (Hendersonville, TN, USA) were used in this study.  Housing, feed rations, 
animal care guidelines, and sampling protocols were approved and supervised by the PIC 
USA Health Assurance and Welfare department.  In 3 trials of 24 boars each, animals were 
intramuscularly (i.m.) inoculated with either modified-live virus (MLV) PRRSV vaccine 
(Trial 1), a Type 1 field isolate (Trial 2), or a Type 2 field isolate (Trial 3).  Serum and oral 
fluid samples were collected from all boars beginning 7 days prior to inoculation and 
continuing through 21 days post inoculation (DPI).  After the completion of Trial 3, samples 
were completely randomized and tested for PRRSV IgM, IgA, and IgG antibody isotypes.  
Descriptive and comparative statistical analyses were conducted to describe and compare 
PRRSV antibody responses in serum and oral fluid and evaluate differences among 
individual boars and between trials.   
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Animals and animal care 
Boars were obtained from two Midwest USA breeding stock sources documented to be free 
of PRRSV infection.  Culled boars (n = 24) ranged from one year to 3.6 years of age and 
select boars (n = 48) ranged from 5 to 6 months of age.  The boars were housed in a 
commercial production facility equipped with nipple drinkers, concrete slatted flooring, 
curtains, and tunnel ventilation.  Feeder space, water delivery, square footage per animal, 
sanitation, and ventilation parameters met or exceeded PIC North America health assurance 
and welfare requirements.  Upon arrival, animals were housed individually in crates (Hog 
Slat, Inc., Newton Grove, NC USA) and fed a commercial corn/soy swine diet (Land O' 
Lakes® Farmland Feed, Roland, IA USA) at a rate of 4 pounds per animal per day for 
acclimation/training and 7 pounds per animal per day thereafter.    
 
Porcine reproductive and respiratory syndrome viruses 
In Trial 1, 24 boars were inoculated i.m. with 2 ml of a commercial MLV vaccine (Ingelvac® 
PRRS MLV, Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506) rehydrated and 
administered according to the instructions provided by the manufacturer.  In Trial 2, 24 boars 
were inoculated i.m. with 2 ml of a Type 1 PRRSV (isolate D09-012131) at an estimated 
concentration of 1 x 105.5 median tissue culture infectious dose (TCID50) per ml.  Isolate 
D09-012131 was isolated from serum samples submitted to the University of Minnesota 
Veterinary Diagnostic Laboratory (St. Paul, MN USA) in March 2009 as part of a routine 
monitoring program in a sow herd located in Illinois USA and propagated on pulmonary 
alveolar macrophage cells, as described elsewhere [11].  In Trial 3, 24 boars were IM 
inoculated with 2 ml of a Type 2 PRRSV isolate (MN-184, GenBank accession no. 
AY656992) at a concentration of 1 x 104.5 TCID50 per ml.  Isolate MN-184 (kindly provided 
by Dr. Scott Dee, University of Minnesota) was propagated on MARC-145 cells [23].   
 
Sample collection 
Oral fluid collection 
Oral fluid samples were collected daily from individually-housed boars beginning 7 days 
prior to inoculation and continuing through 21 days post inoculation (DPI) using a procedure 
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described by Kittawornrat et al. [11].  In brief, oral fluid samples were collected by allowing 
boars to chew on 1.6 cm (5/8”) cotton rope (Web Rigging Supply, Inc., Lake Barrington, IL 
USA).  Prior to collection, ropes were soaked with a solution of sucrose and apple juice 
(unsweetened apple juice with 50% (v/v) sucrose) and then air-dried.  To collect oral fluid 
samples, ropes were placed in “rope holders” fixed at the front of each pen for 20 minutes.  
Oral fluids were deposited as the boars chewed on the rope.  To recover the oral fluid 
specimens, the bottom 15 cm (~6") of the rope (wet portion) was inserted into a 3.8 liter (one 
gallon) re-sealable plastic bag and severed from the dry portion of the rope.  The bag with the 
wet rope inside was passed through a wringer (Dyna-Jet Products, Overland Park, KS USA), 
causing the fluid to pool in the bottom of the bag.  Samples were then decanted into a 50 ml 
centrifuge tube and the volume recorded.  Thereafter, samples were centrifuged at 1,000 x g 
for 10 minutes at 4°C, aliquoted into 5 ml plastic tubes (Becton, Dickinson and Company, 
Bedford, MA USA), and stored at -80°C until assayed.  
 
Serum collection 
In each trial, serum samples were collected from all boars on DPI -7, 0, 7, 14, and 21.  
Additional serum samples were collected on DPI 3, 5, 10, 17 from a subset of boars (n = 4) 
randomly selected at the beginning of each trial.  Blood was collected by jugular 
venipuncture using serum separation tubes (Corvac®, Tyco Healthcare Group LP, Mansfield, 
MA USA).  Samples were centrifuged at 1,000 x g for 10 minutes and the serum was 
aliquoted into 5 ml plastic tubes (Becton, Dickinson and Company) and stored at -80ºC until 
assayed.   
 
PRRSV antibody ELISAs  
Commercial PRRSV serum antibody ELISA      
All serum samples were assayed for PRRSV antibodies using a commercial indirect ELISA 
(PRRS X3 Ab Test, IDEXX Laboratories, Inc., Westbrook, ME USA) performed according 
to the manufacturer’s instruction.  As recommended by the manufacturer, a positive result 
was defined as a sample-to-positive (S/P) ratio ≥ 0.4.  Modifications to the commercial serum 
ELISA for the detection of antibody isotypes in serum and oral fluid are described below and 
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listed in Table 4.   
 
PRRSV antibody isotypes in serum      
The commercial indirect ELISA (PRRS X3 Ab Test) was modified to detect PRRSV-specific 
IgM, IgA, and IgG antibody isotypes in serum.  In brief, serum samples were diluted 1:40 
(5µl serum sample + 195µl kit diluent) for IgM and IgG and 1:5 (40µl serum sample + 160 
µl kit diluent) for IgA.  100 µl of diluted serum was then transferred to the PRRSV antigen-
coated plates and incubated for 30 minutes at 22°C.  After washing 3 times with 1X kit wash 
solution (400 µl), appropriately diluted horseradish peroxidase (HRPO)-conjugated anti-pig 
immunoglobulin (Ig) antibody (IgM (A100-100P), IgA (A100-102P), or IgGFc  (A100-104P) 
(Bethyl Laboratories, Montgomery, TX USA) was added to each well and incubated for 30 
minutes at 22°C.  Thereafter, plates were washed three times with kit washing solution, after 
which 100µl of tetramethylbenzidine (TMB) was added to each well and the plates incubated 
at 22°C for 15 minutes.  At precisely 15 minutes, 100 µl of kit stop solution was added to 
each well.  The plates were read at 650 nm using an ELISA plate reader (EL800 micro plate 
reader, Bio Tek® Instruments Inc., Winooski, VT) controlled by commercial software 
(Gen5TM Bio Tek® Instruments Inc., Winooski, VT USA) and the reactions measured as 
optical density (OD).  
 
PRRSV antibody isotypes in oral fluid      
Modification of the commercial PRRSV ELISA for the detection of PRRSV-specific IgM, 
IgA, and IgG antibody in swine oral fluid has previously been described [5].  In brief, oral 
fluid samples were diluted 1:2 (150 µl oral fluid sample + 150 µl kit diluent).  250 µl of 
diluted oral fluid was then transferred to PRRSV antigen-coated plates and incubated for 16 
hours at 4°C.  Thereafter, the plates were washed three times with 400 µl of 1X kit wash 
solution.  To detect the reaction, 100 µl of a solution containing appropriately diluted HRPO-
conjugated anti-pig Ig (M, A, or G) was added to each well and the plates incubated for 30 
minutes at 22°C.  The procedure for determining the optimal dilution of secondary antibody 
is described in preparation of secondary antibody section.  After washing three times, 100 µl 
of TMB was added to each well and the plates incubated at 22°C for 15 minutes.  Finally, 
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100 µl of kit stop solution was added to each well.  As described in preparation of secondary 
antibody section, the plates were read at 650 nm and the reactions measured as optical 
density (OD). 
 
Preparation of secondary antibody      
To assure assay repeatability, the concentration of anti-pig Ig (M, A, or G) was standardized 
using the positive control OD value listed in the manufacturer’s Certificate of Analysis as the 
benchmark.  The general procedure for calculating the conjugate dilution was as follows:  4 
dilutions of anti-pig Ig (M, A, or G) were prepared in bottles wrapped in aluminum foil using 
diluent provided by manufacturer (IDEXX Laboratories, Inc., Westbrook, MA USA) and 
then stirred for 48 hours at 4°C.  The reactivity of the 4 dilutions was determined using 
negative and positive kit controls.  Specifically, kit negative control was dispensed into 48 
wells (one-half plate) and kit positive control in each of the remaining 48 wells (Figure 4).  
Negative control OD values were used to screen for non-specific reactions and positive 
control OD values were used to determine the equation of the line: 
 
y = ax + c (1) 
 
where (y) is the anti-pig Ig (M, A, or G) OD response, (a) is the slope of the line, (x) is the 
dilution of anti-pig Ig (M, A, or G), and (c) is the intercept (Figure 5).  Thereafter, the correct 
dilution of anti-pig Ig (M, A, or G) was calculated by substituting the mean positive control 
OD from the Certificate of Analysis for “y” in Equation 1 and solving for “x”.   
 
The general procedure for preparing the appropriate dilution of anti-pig Ig (M, A, or G) was 
modified for serum and oral fluid antibody ELISAs.  In this study, all serum and oral fluid 
specimens were tested on a single lot of ELISA kits.  Thus, the appropriate dilution of anti-
pig Ig was calculated specifically for the PRRSV indirect ELISA (PRRS X3 Ab Test) kit lot 
(#99-40959-W721).   
 
For the serum ELISA, the correct dilution of anti-pig IgGFc was determined by titrating 4 
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dilutions of anti-pig IgGFc (1:14,000, 1:14,500, 1:15,000, 1:15,500) against 100 µl of kit 
positive control and generating the equation of the line, as described above.  The appropriate 
dilution of anti-pig IgM was determined by titrating 4 dilutions of secondary antibody 
(1:4,000, 1:4,500, 1:5,000, 1:5,500) against 100 µl of a positive control consisting of a 1:40 
dilution of a pool of serum from 72 boars at DPI 7.  For anti-pig IgA, 4 dilutions (1: 1,000, 
1:2,500, 1:3,000, 1:3,500) were titrated against 100 µl of a positive control consisting of a 
1:5 dilution of a pool of serum from 72 boars at DPI 21.  Diluted conjugate was 
simultaneously titrated against negative controls, i.e., kit negative control for anti-pig IgGFc 
and a pool of serum from 72 boars at DPI 0 for anti-pig IgA (1:5) and anti-pig IgM (1:40).   
 
The protocol for preparing the optimal secondary antibody dilution for the PRRSV oral fluid 
ELISA has been described elsewhere [5].  To prepare anti-pig IgGFc, 4 conjugate dilutions 
(1:1,000, 1:1,500, 1:2,000, 1:2,500) were titrated against 100 µl of kit negative and positive 
controls diluted 1:30 (10 µl kit control + 290 µl kit sample diluent).  Controls for anti-pig 
IgM and anti-pig IgA consisted of oral fluid samples from PRRSV-negative pigs vaccinated 
with 2 ml of PRRS modified live virus (MLV) vaccine (Ingelvac® PRRS MLV, Boehringer 
Ingelheim Vetmedica, Inc., St. Joseph, MO USA).  The sample collected immediately prior 
to vaccination was used as negative control.  Samples collected on 10 and 56 days post 
vaccination were used as positive controls for anti-pig IgM and anti-pig IgA conjugates, 
respectively.   Four dilutions of anti-pig IgM (1: 3,000, 1:3,500, 1:4,000, 1:4,500) and anti-
pig IgA (1:1,000, 1:1,500, 1:2,000, 1:2,500) were used to calculate appropriate dilution, as 
described previously. 
 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR)      
Detailed qRT-PCR protocols for serum and oral fluids are reported elsewhere [11, 24].  In 
brief, nucleic acid extraction from serum and oral fluid samples was performed using a 
commercial RNA extraction kit (Ambion® MagMaxTM-96 Viral RNA isolation kit, Applied 
BiosystemsTM, Foster City, CA USA).  Real-time PCR was performed with commercial 
reagent sets (TaqMAN® NA and EU PRRSV Reagents and TaqMAN® NA and EU PRRSV 
Controls, Applied BiosystemsTM) using the following cycling conditions: 1 cycle at 45 ºC for 
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10 minutes, 1 cycle at 95 ºC for 10 minutes, 40 cycles of: 97 ºC for 2 seconds, 60 ºC for 40 
seconds.  Eight 10-fold serially-diluted (100 to 107 copies/µl) plasmid-derived commercial 
standards (TaqMAN® NA and EU PRRSV RNA controls, Applied BiosystemsTM) were run 
on each PCR plate and their Ct values used to derive a standard curve.  Samples were 
quantified as genome equivalents per µl (geq/µl) by fitting the sample Cts to the standard 
curve using the AB7500 Fast System SDS Software (Applied BiosystemsTM). 
 
Statistical analysis 
All optical density (OD) data were converted to sample-to-positive (S/P) ratios prior to 
statistical analysis using the following formula: 
 
S/P = [Sample A (650) – NC] / (PC – NC) (2) 
  
where NC and PC represented the mean OD of the two negative control wells and two 
positive control wells, respectively.  Statistical analyses were performed using SAS® 
Version 9.2 (SAS® Institute Inc., Cary, NC USA) and MedCalc® 12.3.0.0 (MedCalc 
Software, Mariakerke Belgium).   
 
Initially, descriptive and comparative analyses were conducted to describe the onset, 
magnitude, and duration of PRRSV antibody isotype S/P ratios in serum and oral fluid.  
Thereafter, S/P results were analyzed in a linear mixed model with repeated measures (SAS® 
PROC GLIMMIX) using trial (1, 2, 3), DPI, boar age (month), oral fluid volume (ml), and 
their pairwise interactions as fixed effects and "boar" as the subject of repeated measures.  
Tukey’s Honestly Significantly Difference (HSD) test was used to detect statistically 
significant differences between S/P ratios in each trial by DPI.  Pearson’s correlation 
coefficient (SAS® PROC CORR) was used to evaluate the overall quantitative relationship 
between IgM, IgA, and IgG S/P ratios in serum and oral fluid samples.  Defining an S/P ratio 
≥ 0.4 as positive (Kittawornrat et al., 2012), McNemar's test (SAS® PROC FREQ) for paired 
samples was used to determine whether the proportion IgG ELISA positive serum and oral 
fluid samples were significantly different by trial (1, 2, 3) and DPI.   
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The association between the level of PRRSV replication and the strength of the humoral 
response was evaluated in individual boars.  The virus concentration (loge geq/µl) and 
antibody isotype S/P responses (IgM, IgA, IgG) in serum and oral fluid over the course of the 
experiment were re-expressed as the area under the curve (AUC; MedCalc®) and evaluated 
using   
Pearson's Correlation Coefficient (SAS® PROC CORR).  In addition, the AUC data were 
evaluated for statistically significant differences among sample types (serum, oral fluid), 
trials (1, 2, 3), and quantitative responses (PRRSV, IgM, IgA, IgG) by analysis of variance 
(ANOVA).  Sample type, trial, response, and their interaction were used as fixed effects in 
the model.  Thereafter, Tukey’s Honestly Significant Differences (HSD) test was used to test 
for statistically significant differences among trial means.   
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Table  1.  Porcine reproductive and respiratory syndrome virus (PRRSV) antibody isotypes (IgM, IgA, and IgG) in oral 
fluid and serum samples collected from boars over day post inoculation (DPI) 
DPI  Serum (mean S/P ratios)
a  Oral fluid (mean S/P ratios)a 
Samples  IgM  IgA  IgG  Samples  IgM  IgA  IgG 
‐7  72  0.10 d  0.35 b  0.03 d  70  0.02 g  0.15 g  0.01 i 
0  72  0.19 d  0.31 b  0.03 d  68  0.02 g  0.08 g  0.01 i 
1  ‐  ‐  ‐  ‐  69  0.04 g  0.12 g  0.01 i 
2  ‐  ‐  ‐  ‐  68  0.04 g  0.13 g  0.02 i 
3  12  0.05 d  0.23 b  0.01 d  70  0.07 g  0.16 g  0.02 i 
4  ‐  ‐  ‐  ‐  68  0.13 g  0.24 g  0.01 i 
5  12  0.12 d  0.30 b  0.02 d  67  0.05 g  0.11 g  0.01 i 
6  ‐  ‐  ‐  ‐  66  0.09 g  0.12 g  0.01 i 
7  72  0.82 c  0.58 b  0.05 d  69  0.30 f  0.23 g  0.03 i 
8  ‐  ‐  ‐  ‐  66  1.28 e  0.41 f  0.17 h 
9  ‐  ‐  ‐  ‐  66  2.32 c  0.95 e  0.59 g 
10  12  3.56 b  1.70 a  0.87 c  70  2.72 b  1.45 b, c  0.99 f 
11  ‐  ‐  ‐  ‐  70  2.95 a  1.75 a  1.41 e 
12  ‐  ‐  ‐  ‐  70  2.70 b  1.59 a, b  1.78 d 
13  ‐  ‐  ‐  ‐  69  2.64 b  1.64 a  2.05 c 
14  72  4.02 a  1.91 a  1.60 b  68  2.32 c  1.56 a, b  2.28 b 
17  12  3.51 b  1.94 a  1.69 a, b  69  1.53 d  1.25c,d  2.63 a 
21  72  3.18 b  1.70 a  1.76 a  68  1.02 e  1.14 d, e  2.60 a 
 
a Within columns, different superscripted letters denote statistically significant differences between means (p < 0.05) 
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Table  2.  Porcine reproductive and respiratory syndrome virus (PRRSV) serum1 and oral fluid2 ELISA qualitative results3 
by day post inoculation (DPI) 
 
Trial (virus isolate) Sample DPI 0 positive / tested 
DPI 7 
positive / tested 
DPI 14 
positive / tested 
DPI 21 
positive / tested 
Trial 1: (Ingelvac® PRRS MLV) Oral fluid 0 / 24 0 / 24 24 / 24  24 / 24  Serum 0 / 24 0 / 24 24 / 24  24 / 24  
Trial 2: (Type 1, D09-012332) Oral fluid 0 / 22 0 / 22 17 / 21  22 / 22  Serum 0 / 24 0 / 24  22 / 24  24 / 24  
Trial 3: (Type 2, MN-184) Oral fluid 0 / 24 0 / 23 24 / 24  22 / 22  Serum 0 / 24 0 / 24  24 / 24  24 / 24  
TOTAL Oral fluid 0 / 70 0 / 69  65 / 69  68 / 68  
Serum 0 / 72 0 / 72 70 / 72  72 / 72  
 
a PRRS X3 Ab Test (IDEXX Laboratories, Inc, Westbrook, Maine, USA) performed according to the manufacturer’s instruction.   
b PRRS X3 Ab Test (IDEXX Laboratories, Inc, Westbrook, Maine, USA) modified to detect anti-PRRSV antibody in oral fluid 
specimens (Kittawornrat et al., 2012).   
c Samples with S/P ratio ≥ 0.4 were classified as positive  
 
  
  
72 
 
Table  3.  Comparison of cumulative quantitative reverse transcription polymerase chain reaction (qRT-PCR) and 
antibody responses (IgM, IgA, IgG) for 21 days following PRRSV inoculation 
 Serum (mean AUC and 95% confidence intervals) Oral fluid (mean AUC and 95% confidence intervals) 
Trial (virus isolate) qRT-PCR IgM IgA IgG qRT-PCR IgM IgA IgG 
Trial 1: (Ingelvac® 
PRRS MLV) 
21.6b 
(18.8-24.5) 
46.6b 
(43.1-50.2) 
18.5b 
(14.6-22.6) 
17.4a 
(15.9-18.9) 
21.0b 
(17.0-25.1) 
27.6b 
(23.9-31.5) 
12.3b 
(7.7-17.0) 
25.1b 
(20.6-29.6) 
Trial 2: (Type 1, 
D09-012332) 
23.8b 
(21.2-26.6) 
39.5b 
(31.1-48.0) 
30.0a 
(23.2-36.9) 
18.3a 
(16.5-20.2) 
21.2b 
(18.1-24.3) 
17.6c 
(12.0-23.2) 
17.9b 
(10.9-24.9) 
21.9b 
(16.7-27.2) 
Trial 3: (Type 2, MN-
184) 
38.1a 
(34.9-41.5) 
53.7a 
(48.1-59.3) 
31.6a 
(24.7-38.5) 
18.4a 
(17.1-19.85) 
31.6a 
(28.4-34.9) 
35.4a 
(28.6-42.3) 
26.2a 
(19.1-33.5) 
30.1a 
(25.3-34.9) 
 
1 Individual boar PRRSV (loge geq/µl) and antibody (IgM, IgA, IgG) S/P responses over time were summarized as the area under 
the curve (AUC) prior to performing the statistical analysis.   
abc Superscripts within columns indicate statistically significant differences among means (Tukey’s Honestly Significant 
Differences test, p < 0.05).  
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Table  4.  Summary of porcine reproductive and respiratory syndrome virus (PRRSV) serum and oral fluid antibody 
enzyme linked-immunosorbent assay (ELISA) condition 
 IgM IgA IgG Commercial ELISA 
Serum ELISAs     
Sample dilution 1:40 1:5 1:40 1:40 
Sample volume 100 µl 100 µl 100 µl 100 µl 
Conjugate dilution 1:5,000b 1:1,000c 1:15,000d Provided with kit 
Negative control 100 µl of pooled negative 
serum diluted 1:40 
100 µl of pooled negative 
serum diluted 1:5 
100 µl of kit negative control 100 µl of kit negative control 
Positive control 100 µl of pooled serum from 
DPI 7 diluted 1:40 
100 µl of pooled serum from 
DPI 21 diluted 1:5 
100 µl of kit positive control  100 µl of kit positive control 
Oral fluid ELISAs     
Sample dilution 1:2 1:2 1:2  
Sample volume 250 µl 250 µl 250 µl  
Conjugate dilution 1:3,800b 1:2,000c 1:2,400d  
Negative control 250 µl of reference standard 
oral fluide DPI 0 diluted 1:2 
250 µl of reference standard 
oral fluide DPI 0 diluted 1:2 
100 µl of kit negative control 
diluted 1:30 
 
Positive control 250 µl of reference standard 
oral fluide DPI 10diluted 1:5 
250 µl of reference standard 
oral fluide DPI 91 diluted 1:2 
100 µl of kit positive control 
diluted 1:30 
 
a Oral fluid ELISA conditions represent modifications to a commercial PRRSV serum antibody ELISA protocol (IDEXX PRRS 
X3 Ab Test, IDEXX Laboratories, Inc., Westbrook, ME, USA) 
b Anti-pig IgM: HRPO conjugate (A100-100P, Bethyl Laboratories, Montgomery, TX, USA) 
c Anti-pig IgA: HRPO conjugate (A100-102P, Bethyl Laboratories, Montgomery, TX, USA) 
d Anti-pig IgGFc: HRPO conjugate (A100-104P, Bethyl Laboratories, Montgomery, TX, USA) 
e Reference standard oral fluid samples have been described by Kittawornrat et al (2012).   
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Figure 1.  Kinetics of PRRSV antibody isotypes (IgM, IgA, and IgG) in serum based on 
responses in 72 boars inoculated with 3 different PRRSV isolates.   
Results are reported as mean sample-to-positive (S/P) ratios and standard errors.   
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Figure 2.  Kinetics of PRRSV antibody isotypes (IgM, IgA, and IgG) in oral fluid based 
on responses in 70 boars inoculated with 3 different PRRSV isolates.   
Results are reported as mean sample-to-positive (S/P) ratios and standard errors. 
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Figure 3.  Correlation between serum and oral fluid PRRSV antibody isotypes (IgM, 
IgA, and IgG) based on results from individual boars  
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Figure 4.  Microtitration plate map for titrating anti-pig immunoglobulin (M, A, or G) 
antibody.   
 
The reactivity of the 4 dilutions was determined using negative and positive controls.  
Negative control OD values were used to screen for non-specific reactions.  Positive control 
OD values were used to calculate the equation of the line (y = ax + c), where (y) is the anti-
pig immunoglobulin (M, A, or G) OD response, (a) is the slope of the line, (x) is the dilution 
of anti-pig Ig (M, A, or G) antibody, and (c) is the intercept (Figure 2).  The correct dilution 
of anti-pig Ig (M, A, or G) was calculated by substituting the mean positive control OD from 
the ELISA kit Certificate of Analysis for “y” in Equation 1 and then solving for “x”.   
  
 Dilutions of anti-pig immunoglobulin  
Dilution 1 Dilution 2 Dilution 3 Dilution 4 
1 2 3 4 5 6 7 8 9 10 11 12 
N
eg
at
iv
e 
C
on
tro
l 
A 1 5 9 1 5 9 1 5 9 1 5 9 
B 2 6 10 2 6 10 2 6 10 2 6 10 
C 3 7 11 3 7 11 3 7 11 3 7 11 
D 4 8 12 4 8 12 4 8 12 4 8 12 
Po
si
tiv
e 
C
on
tro
l 
E 13 17 21 13 17 21 13 17 21 13 17 21 
F 14 18 22 14 18 22 14 18 22 14 18 22 
G 15 19 23 15 19 23 15 19 23 15 19 23 
H 16 20 24 16 20 24 16 20 24 16 20 24 
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Figure 5.  Calculation of the optimal dilution of anti-pig secondary antibody for PRRSV 
IgM, IgA, IgG ELISAs.   
 
The relationship between the positive control optical density (OD) and dilution of anti-pig 
secondary antibody was plotted as y = ax + c, where (y) is the secondary antibody OD 
response, (a) is the slope of the line, (x) is the dilution of secondary antibody, and (c) is the 
intercept.  The appropriate dilution corresponds to the positive control value provided in the 
manufacturer's Certificate of Analysis.  
  
79 
 
 
CHAPTER 6.  PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME 
VIRUS (PRRSV) SURVEILLANCE USING PRE-WEANING ORAL FLUID 
SAMPLES DETECTS CIRCULATION OF WILD-TYPE PRRSV 
 
Apisit Kittawornrat, Yaowalak Panyasing, Christa Goodell, Chong Wang, Phil Gauger, 
Karen Harmon, Rolf Rauh, Luc Desfresne, Ian Levis, Jeffrey Zimmerman 
 
A paper submitted to Veterinary Microbiology 
 
ABSTRACT 
Oral fluid samples collected from litters of piglets (n = 600) one day prior to weaning were 
evaluated as a method to surveil for porcine reproductive and respiratory syndrome virus 
(PRRSV) infections in four ~12,500 sow herds.  Serum samples from the litters' dam (n = 
600) were included for comparison.  All four herds were endemically infected with PRRSV 
and all sows had been vaccinated ≥ 2 times with PRRSV modified-live virus vaccines.  After 
all specimens had been collected, samples were randomized and assayed for PRRSV nucleic 
acid by real-time reverse transcription polymerase chain reaction (RT-qPCR) and anti-
PRRSV antibodies using four PRRSV ELISA assays (IgM, IgA, IgG, and Commercial Kit).  
All sow serum samples were negative by PRRSV RT-qPCR, but 9 of 600 oral fluid samples 
tested positive at two laboratories.  Two of the 9 positive oral fluid samples were sequenced 
(open reading frame 5) and the presence of nucleic acid from wild-type viruses was detected.  
A comparison of antibody responses in RT-qPCR positive vs. negative oral fluid samples 
showed significantly higher IgG S/P ratios in RT-qPCR-positive oral fluid samples (mean 
S/P 3.46 vs. 2.36; p = 0.02).  Likewise, sow serum samples from RT-qPCR-positive litter 
oral fluid samples showed significantly higher serum IgG (mean S/P 1.73 vs. 0.98; p < 0.001) 
and Commercial Kit (mean S/P 1.97 vs. 0.98; p < 0.001) S/P ratios.  Overall, this study 
showed that pre-weaning litter oral fluid samples could provide an efficient and sensitive 
approach to surveil for PRRSV in infected, vaccinated, or presumed-negative pig breeding 
herds.  
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INTRODUCTION 
Cost-effective methods of disease surveillance are needed to provide timely information on 
the presence and/or distribution of pathogens in swine herds, support animal health and 
business decisions at the herd level, and improve the quality of field research.  Current 
methods of surveillance in pig populations are primarily based on labor-intensive sampling 
methods, i.e., blood collection from individual animals.  As a result, routine herd surveillance 
is cost-prohibitive and generally under-utilized.   
 
The current body of literature provides evidence that oral fluid sampling could provide a 
cost-effective and welfare-friendly alternative to serum-based surveillance.  That is, a variety 
of pathogens and pathogen-specific antibody can be detected in pig oral fluids, e.g., classical 
swine fever virus (Corthier, 1976; Corthier and Aynaud, 1977), porcine circovirus type 2 
(Prickett et al., 2011), swine influenza virus (Panyasing et al., 2012), transmissible 
gastroenteritis virus (DeBuysscher and Berman, 1980), Actinobacillus pleuropneumoniae 
(Loftager et al., 1993), E. coli (De Buysscher and Dubois, 1978), Erysipelothrix 
rhusiopathiae (Giménez-Lirola et al., 2013), and others.  For PRRSV, research has described 
the pattern of viral shedding (Kittawornrat et al., 2010; Prickett et al., 2008) and the ontogeny 
of the anti-PRRSV humoral response (Kittawornrat et al., 2012a,b; 2013) in oral fluids.   
 
The need for efficient, effective surveillance is particularly true for porcine reproductive and 
respiratory syndrome virus (PRRSV), which remains one of the most costly diseases of swine 
worldwide, imposing significant losses on North American (Holtkamp et al., 2013; Sierra et 
al., 2000), European (Velasova et al., 2012) and Asian producers (Tian et al., 2007).  Based 
on our cumulative global experience, it would seem that achieving control of PRRSV will 
require that animal health specialists develop the capacity to easily, efficiently, and 
continuously surveil herds for PRRSV.  Therefore, the purpose of the present study was to 
evaluate a method to detect PRRSV circulation in the breeding herd and growing pig 
populations based on collection and testing of oral fluid samples prior to weaning. 
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MATERIALS AND METHODS 
Experimental design           
In four PRRSV vaccinated commercial swine herds, oral fluid samples were collected from 
600 litters 24 hours prior to weaning and serum samples from their dams two days post 
weaning.  Thereafter, samples were completely randomized and tested for PRRSV (RT-
qPCR and sequencing) and PRRSV antibodies using commercial ELISA Kits (PRRS X3 Ab 
Test and PRRS Oral Fluids Ab Test, IDEXX Laboratories, Inc., Westbrook, ME) and 
antibody isotype-specific assays (IgM, IgA, and IgG).  In addition, PRRSV ORF5 
sequencing was attempted on RT-qPCR-positive samples.  Virus and antibody assay results 
were analyzed for associations with farm, sow parity, litter size, time, and infection status.   
 
Animals and animal care          
The study was performed in four ~12,500 sow breeding herds.  Animal housing, feeding, 
handling, and veterinary care were under the supervision of Seaboard L.L.C. Health 
Assurance and Welfare personnel.  Sample collection protocols were approved by the Iowa 
State University Institutional Animal Care and Use Committee (#8-11-7202-S).   
 
All four herds were considered to be endemically infected with PRRSV on the basis of 
diagnostic history and on-going surveillance.  Commercial PRRSV vaccines were used to 
control clinical losses, with some differences in the vaccination protocols among sites.  In all 
four herds, replacement gilts were vaccinated with a commercial modified-live (MLV) 
PRRSV vaccine (Ingelvac MLV®, Boehringer Ingelheim Vetmedica, Inc., St. Joseph. MO) at 
weeks 0 and 2 of quarantine, i.e., prior to entering the sow farm.  Once entered into the sow 
farms, all gilts and sows were routinely vaccinated with either PRRSV MLV or PRRSV ATP 
vaccines (Ingelvac ATP®, Boehringer Ingelheim Vetmedica, Inc., St. Joseph. MO) according 
to a schedule based on the weeks of the calendar year.  Animals in Herd 1 were vaccinated 
with PRRSV ATP vaccine at weeks 9 and 13.  Herd 2 animals were vaccinated with PRRSV 
ATP at weeks 1, 4, 47, and 51 and PRRSV MLV at week 5.  Herd 3 used PRRSV ATP at 
weeks 2, 20, and 24, and Herd 4 vaccinated all animals with PRRSV ATP at week 1 and 
MLV at week 5.   
82 
 
 
Sample collection 
Oral fluid specimens were collected from litters of pigs to be weaned and serum from their 
dams over a period of four months, as shown in Table 1.  Oral fluid samples were collected 
from litters of piglets by farrowing room personnel one day prior weaning.  Piglets averaged 
17 days of age (range: 15 to 19 days) at the time of collection.  The oral fluid collection 
procedure has been fully described by Kittawornrat et al. (2010).  In brief, oral fluid samples 
were collected in the morning (when piglets were active) by suspending 1.25 cm (0.5 inch) 
unbleached cotton rope (Web Rigging Supply, Inc., Lake Barrington, IL USA) over the heat 
mat area, thereby providing access to the piglets, but not the sow.  The ropes were hung until 
they were wet (15 minutes to 2 hours), after which the wet portion of the rope was inserted 
into a single-use re-sealable plastic bag and the fluid extracted by manually squeezing the 
rope inside the plastic bag.  The oral fluid sample was then decanted into a tube, immediately 
chilled, refrigerated overnight, and shipped to the laboratory on the following day.  At the 
laboratory, oral fluid samples were aliquoted into 5 ml cryogenic vials and stored at -80ºC.  
Within 48 hours of collecting oral fluids, serum samples were collected from sows using a 
single-use blood collection system (Corvac®, Tyco Healthcare Group LP, Mansfield, MA 
USA). Samples were transported to the laboratory in blood tubes.  At the laboratory, samples 
were centrifuged at 1,000 x g for 10 minutes, after which the serum was aliquoted into 5 ml 
plastic tubes and stored at -80ºC.  When all samples had been collected, they were placed in 
random order and submitted for testing.   
 
PRRSV antibody ELISAs  
Commercial Kit (serum)      
All serum samples were assayed for PRRSV antibodies using a commercial indirect ELISA 
(PRRS X3 Ab Test, IDEXX Laboratories, Inc., Westbrook, ME) performed according to the 
manufacturer’s instruction.  Using the formula provided by the manufacturer, a positive 
result was defined as a sample-to-positive (S/P) ratio ≥ 0.4.     
 
PRRSV antibody isotypes in serum      
The commercial indirect ELISA (PRRS X3 Ab Test) was modified to detect PRRSV-specific 
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IgM, IgA, and IgG antibody isotypes in serum.  In brief, serum samples were diluted 1:30 
(5µl serum sample + 145µl kit diluent) for IgM, 1:20 (10µl serum sample + 190 µl kit 
diluent) for IgA and 1:40 (5µl serum sample + 195 µl kit diluent) for IgG.  100 µl of diluted 
serum was then transferred to the PRRSV antigen-coated plates and incubated for 30 minutes 
at 22 ̊C.  After washing 3 times with 1X kit wash solution (400 µl), appropriately-diluted 
horseradish peroxidase (HRPO)-conjugated anti-pig IgM antibody (1:5,000; A100-100P, 
Bethyl Laboratories, Montgomery, TX), anti-pig IgA antibody (1:1,000; A100-102P), or 
anti-pig IgGFc antibody (1:18,000; A100-104P) was added to each well and incubated for 30 
minutes at 22 ̊C.  Thereafter, plates were washed three times with kit washing solution, after 
which 100µl of tetramethylbenzidine (TMB) was added to each well and the plates incubated 
at 22 ̊C for 15 minutes.  At precisely 15 minutes, 100 µl of kit stop solution was added to 
each well.  Negative and positive serum controls were created by pooling serum from boars 
of precisely known PRRSV infection status (Kittawornrat et al., 2013).  Negative control 
serum for IgM and IgA assays consisted of pooled serum collected on day post inoculation 
(DPI) 0.  Pooled serum samples collected on DPI 7 and 21 were used as positive controls for 
serum IgM and IgA assays, respectively.  The IgG assay used the negative and positive 
controls provided by the manufacturer.  The plates were read at 650 nm using an ELISA 
plate reader (EL800 micro plate reader, Bio Tek® Instruments Inc., Winooski, VT) 
controlled by commercial software (Gen5TM, Bio Tek® Instruments Inc.) and the reactions 
measured as optical density (OD).  Based on previous work (Kittawornrat et al., 2012), a 
positive results for the IgG assay was defined as a S/P ratio ≥ 0.4. 
 
Commercial Kit (oral fluid) 
All oral fluid samples were assayed for PRRSV antibodies using a commercial indirect 
ELISA (PRRS Oral Fluids Ab Test) performed according to the manufacturer’s instruction.  
In brief, oral fluid samples were diluted 1:2 (100 µl oral fluid sample + 100 µl kit diluent).  
100 µl of diluted oral fluid was then transferred to PRRSV antigen-coated plates and 
incubated for 2 hours at 22 ̊C.  Thereafter, the plates were washed 4 times with 400 µl of 1X 
kit wash solution.  To detect the reaction, 100 µl of kit conjugate was added to each well and 
the plates incubated for 30 minutes at 22 ̊C.  After washing 4 times, 100 µl of TMB substrate 
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N.12 was added to each well and the plates incubated at 22 ̊C for 15 minutes.  Finally, 100 µl 
of kit stop solution was added to each well. The plates were read under dual-wavelength 
setting at 450-650 nm and the reactions measured as OD.  Using the formula provided by the 
manufacturer, a positive result was defined as a sample-to-positive (S/P) ratio ≥ 0.4.     
 
PRRSV antibody isotypes in oral fluid      
Modification of the commercial PRRSV ELISA for the detection of PRRSV-specific IgM, 
IgA, and IgG antibody in swine oral fluid has previously been described (Kittawornrat et al., 
2012).  In brief, oral fluid samples were diluted 1:2 (150 µl oral fluid sample + 150 µl kit 
diluent).  250 µl of diluted oral fluid was then transferred to PRRSV antigen-coated plates 
and incubated for 16 hours at 4 ̊C.  Thereafter, the plates were washed 4 times with 400 µl of 
1X kit wash solution.  To detect the reaction, 100 µl of a solution containing appropriately-
diluted HRPO-conjugated anti-pig IgM antibody (1:4,000), anti-pig IgA antibody (1:2,000), 
or anti-pig IgG antibody (1:2,500) was added to each well and the plates incubated for 30 
minutes at 22 ̊C.  After washing 3 times, 100 µl of TMB was added to each well and the 
plates incubated at 22 ̊C for 15 minutes.  Finally, 100 µl of kit stop solution was added to 
each well.  Oral fluid antibody assay controls consisted of oral fluid samples collected from 
PRRSV-negative pigs intramuscularly inoculated with 2 ml of PRRS modified live virus 
(MLV) vaccine (Ingelvac® PRRS MLV, Boehringer Ingelheim Vetmedica, Inc., St. Joseph, 
MO USA).  The sample collected immediately prior to vaccination was used as the negative 
control.  Samples collected on 10 and 56 days post vaccination were used as positive controls 
for IgM and IgA assays, respectively (Kittawornrat et al., 2012).  The IgG assay used the 
negative and positive controls provided by the manufacturer.  As described in 2.6.2, the 
plates were read at 650 nm and the reactions measured as OD.  Based on previous work 
(Kittawornrat et al., 2012), a positive results for the IgG assay was defined as a S/P ratio ≥ 
0.4. 
 
PRRSV real-time reverse transcription polymerase chain reaction (RT-qPCR)  
PRRSV RT-qPCR #1  
All samples (600 serum samples, 600 oral fluid samples) were tested at the Iowa State 
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University - Veterinary Diagnostic Laboratory (ISU-VDL) for the presence of PRRSV.  
RNA extraction was performed using the MagMAX™ Viral RNA Isolation Kit (Life 
Technologies Corporation, Carlsbad, CA) and a Kingfisher 96 instrument (Thermo 
Scientific, Waltham, MA).  Serum was extracted following the standard lysis procedure 
using 50 μl of sample added to 130 μl of lysis-binding solution/carrier RNA prepared 
according to the kit insert, 20 μl magnetic bead mix and 90 μl of elution buffer.  Oral fluids 
were extracted using a high volume modified lysis (HVML) procedure.  The lysis/binding 
solution for the HVML protocol was prepared using 45 ml lysis/binding solution with 200 μl 
carrier RNA without the addition of isopropanol. For the lysis step, 300 μl of sample was 
added to 450 μl of modified lysis/binding solution, vortexed for 3 minutes and centrifuged at 
2,500 x g for 6 minutes.  A volume of 600 μl of lysate was added to 350 μl isopropanol with 
20 μl magnetic bead mix prior to extraction and elution into 90 μl buffer.  The standard lysis 
protocol used 150 μl of wash solution I and II provided with the kit.  The HVML used 300 
and 450 μl of wash solutions I and II, respectively.  The standard lysis extractions were 
conducted using the Kingfisher program AM_1836_DW_50_v3.  The HVML extraction was 
conducted using the Kingfisher AM1836_DW_HV_v3. 
 
RT-qPCR was performed on nucleic acid extracts using a commercially available NA and 
EU PRRSV-specific PCR assay (VetMAXTM TaqMan® NA and EU PRRSV Reagents, Life 
Technologies Corporation).  The assay contained multiple primers and probes to detect and 
differentiate North American (Type II) and European (Type I) strains.  Internal control RNA 
(Xeno™, Life Technologies Corporation) was included in the master mix to monitor PCR 
amplification and detection of PCR inhibition.  Two positive extraction controls, one 
negative extraction control, and a negative amplification control were included with each 
extraction and/or PCR run.  Each serum reaction included 12.5 μl of 2X RT-PCR buffer, 2.5 
μl of 10X PRRSV primer probe mix, 1.25 μl of 20X multiplex RT-PCR enzyme mix, 0.35 μl 
of internal control RNA at a concentration of 100 copies/μl, and 0.4 μl of nuclease-free 
water.  Each oral fluid reaction used the same volume of reagents described for serum, with 
the exception of 2.5 μl of 20X multiplex RT-PCR enzyme mix and 0.5 μl of nuclease-free 
water. A final volume of 25 μl consisting of 17 μl mastermix and 8 μl of RNA extract for the 
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serum samples, or 18 μl mastermix and 7 μl of RNA extract for the oral fluid samples, was 
placed in each well of a 96-well fast PCR plate (Life Technologies Corporation).  RT-qPCR 
was performed (7500 Fast Real-Time PCR System, Applied Biosystems®, Foster City, CA) 
with the following cycling conditions: one cycle at 45°C for 10 min, one cycle at 95°C for 10 
min, and 40 cycles of 97°C for 2 sec, and 60°C for 40 sec.  Amplification curves were 
analyzed with commercial thermal cycler system software.  The “auto baseline” was used to 
determine fluorescence baselines and cycle thresholds were set at 0.1 and 0.05 for NA and 
EU PRRSV, respectively.  Samples with threshold cycle (Ct) values <37 for either strain 
were considered positive.  Internal control Xeno™ RNA Ct values were set at 10% of 
maximum.  Eight progressive 1:10 dilutions of a PRRSV standard supplied with the 
commercial PRRSV PCR kit were used to generate a curve for virus quantification (genomic 
copies per ml) on each plate. 
 
PRRSV RT-qPCR #2  
Samples initially tested at the ISU-VDL were submitted for confirmatory testing at a second 
laboratory (Tetracore, Inc., Rockville, MD).  The sample set included 30 litter oral fluid 
samples (9 PRRSV RT-qPCR-positive samples and 21 blindly selected negatives) and 30 
blindly selected RT-qPCR-negative sow serum samples.  RNA extraction was performed 
using the MagMAXTM Pathogen RNA/DNA Kit (Life Technologies Corporation) and 
BioSprint® 96 Workstation particle processor (Qiagen, Valencia, CA).  Serum was extracted 
following the manufacturer instructions for low-cell-content samples.  Oral fluid samples 
were extracted using the protocol for “all other sample types”.  300 µl of sample (serum or 
oral fluid) was used in the reaction and reagents were prepared accordingly, with the 
exception that 8 µl of in-house control was used in the lysis/binding solution, rather than 2 µl 
of XenoTM RNA (Life Technologies Corporation).  Extraction of both sample types was 
completed using program 4462359_DW_HV. 
 
Real time RT-PCR was performed using an in-house PRRSV RT-PCR assay (Tetracore®, 
Rockville, MD).  The assay covers two target regions of the PRRSV Type 1 and 2 genes 
using FAM as a reporter dye for the detection of the Type 1 PRRSV and TAMRA as a 
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reporter dye for the detection of the Type 2 PRRSV.  CY5 was used as a reporter dye for the 
detection of the extraction/inhibition control.  Serum component volumes per well included 
19.25 µl of master mix (includes buffer, primer and probes), 0.25 µl of enzyme 1, 0.5 µl of 
enzyme 2, and 8 µl of extracted serum sample or internal control.  Oral fluid component 
volumes per well included 16.25 µl of master mix (includes buffer, primer and probes), 0.25 
µl of enzyme 1, 0.5 µl of enzyme 2, and 8 µl of extracted oral fluid sample or internal 
control.  Plates were briefly vortexed (10 sec) and centrifuged before being loaded onto the 
thermal cycler (7500 Fast Real-Time PCR System, Applied Biosystems®, Foster City, CA).  
The reaction was completed using the following thermal cycling conditions: one cycle at 48 
°C for 15 min, one cycle at 95 °C for 2 min, 45 cycles of: 95 °C for 5 seconds, and 60 °C for 
40 seconds.  Samples with Ct values <38 for either strain were considered positive.   
 
PRRSV ORF5 sequencing 
Oral fluid samples were extracted for open reading frame 5 (ORF5) sequencing as described 
above in the nucleic acid extraction protocol for ISU-VDL. Approximately 1082 base pairs 
of the ORF5 region of the PRRSV genome were amplified using forward primer 5’-AAG 
GTG GTA TTT GGC AAT GTG TC-3’ and reverse primer 5’-GAG GTG ATG AAT TTC 
CAG GTT TCT A-3’ and the qScriptTM Custom One-Step RT-PCR Kit (Quanta Biosciences, 
Gaithersburg, MD). The oral fluid sequencing PCR setup reaction used 320 nM of each 
primer with 12.5 μl 2X qScript One-Step master mix, 0.5 μl qScript One-Step reverse 
transcriptase and 7.2 μl nuclease-free water. A final volume of 25 μl consisted of 21 μl 
mastermix and 4 μl of RNA extract. One positive extraction control, one negative extraction 
control and one negative amplification control were included with the reaction. Polymerase 
chain reaction was performed (Applied Biosystems® 2720 thermal cycler, Life Technologies 
Corporation) with the following cycling conditions: one cycle at 48°C for 20 minutes, one 
cycle at 94°C for 3 minutes, 45 cycles of 94°C for 30 seconds, 50°C for 50 seconds, and 
68°C for 50 seconds. The final elongation step was 68°C for 7 minutes. Detection of the RT-
PCR product of the correct size (1082 bp) was performed on a QIAxcel® capillary 
electrophoresis system (Qiagen) using a DNA screening cartridge and the AM420 method 
and purified with ExoSAP-IT® (Affymetrix, Santa Clara, CA) following the manufacturer’s 
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recommendations. Samples were submitted to the Iowa State University DNA Facility for 
sequencing and commercial software was used to compile sequences (Lasergene®, 
DNAStar, Madison, WI). 
 
Statistical analysis 
Statistical analyses were performed using SAS® 9.2 (SAS® Institute Inc., Cary, NC USA) 
and MedCalc® 9.2.1.0 (MedCalc Software, Mariakerke, Belgium).  Serum and oral fluid S/P 
ratios were analyzed for significant associations with sow parity, litter size, herd, sampling 
time point, and their pairwise interactions by analysis of variance (ANOVA).  The overall 
quantitative relationship between IgM, IgA, IgG, and Kit S/P ratios in serum versus oral fluid 
samples was evaluated by correlation analysis.  Qualitative (pos/neg) differences in ELISA 
performance by specimen type were assessed using Cochran’s Q test.  Descriptive and 
comparative analyses were used to evaluate the quantitative (Ct) and qualitative (pos/neg) 
RT-qPCR results in serum and oral fluid samples.  PRRSV ORF5 nucleotide percent identity 
of wild type sequences recovered during the study were compared to wild type isolates 
recovered from the farms either before or after the study, the North American prototype 
PRRSV (VR-2332), and modified live vaccines (Ingelvac MLV® and Ingelvac ATP®) using 
BioEdit 7.1.11 (Ibis Biosciences, Carlsbad, CA). 
 
RESULTS  
PRRSV RT-qPCR results 
Testing of pre-weaning oral fluid samples (n = 600) and sow serum samples (n = 600) using 
Testing of pre-weaning oral fluid samples (n = 600) and sow serum samples (n = 600) using 
PRRSV RT-qPCR #1 resulted in 9 positive oral fluid samples and no positive serum samples.  
The 9 positive samples, 21 blindly-selected oral fluid samples, and 30 blindly-selected serum 
samples were re-tested using PRRSV RT-qPCR #2.  The results of RT-qPCR #2 exactly 
matched the results reported for PRRSV RT-qPCR #1 (Table 4).  Among the 9 PRRSV RT-
qPCR-positive samples, 3 samples had been exhausted.  The remaining 6 samples were 
submitted for PRRSV ORF5 sequencing and sequences were obtained on 2 of the 6 (Table 4 
and 5).  As indicated in Table 5, the sequence from Farm 2 shared 99.0%, 98.1%, and 98.6% 
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ORF5 nucleotide identity with 3 viruses isolated from sow serum samples collected in 
association with clinical PRRSV between 11/2010 and 03/2012.  Likewise, the sequence 
from Farm 3 shared 99.0% ORF5 nucleotide identity with a virus isolated 8 months earlier in 
conjunction with reproductive disease. 
 
A statistical analysis based on PRRSV RT-qPCR quantitative results (Ct values) detected no 
statistically significant associations with farm, sow parity, or their interactions.  However, an 
analysis of antibody responses showed significantly higher IgG S/P ratios in RT-qPCR-
positive versus negative oral fluid samples (mean S/P 3.46 vs. 2.36; p = 0.02).  In contrast, a 
comparison between these two groups detected no significant difference in Commercial Kit 
mean S/P responses (mean S/P 6.19 vs. 4.60; p = 0.07).  Sow serum samples from RT-qPCR-
positive litter oral fluid samples showed significantly higher serum IgG (mean S/P 1.73 vs. 
0.98; p < 0.001) and Commercial Kit (mean S/P 1.97 vs. 0.98; p < 0.001) S/P ratios, but no 
significant difference in IgM or IgA responses.   
 
PRRSV antibody responses in serum and oral fluid samples 
The manufacturer of the PRRSV antibody ELISA provides validity criteria in the kit insert.  
Specifically, for each plate, the mean of the two positive controls minus the mean of the two 
negative controls should be ≥ 0.15 and the mean of the two negative controls must be ≤ 0.15.  
All plates met these criteria with the exception of the serum IgM plates in which the mean of 
the negative control ranged from 0.20 to 0.25.    
 
Qualitative results for the PRRSV Commercial Kit and PRRSV IgG ELISAs are shown in 
Table 2.  A total of 443 (73.8%) sow serum samples were PRRSV antibody positive on the 
Commercial Kit compared to 473 (78.8%) using the serum IgG assay.  In contrast, 594 
(99.0%) litter oral fluid samples were antibody positive on the PRRSV oral fluid Commercial 
Kit vs. 579 (96.5%) on the IgG antibody assay.  Pairwise comparisons detected no 
statistically significant differences between the results produced by the oral fluid Commercial 
Kit and oral fluid IgG ELISAs, but significant differences (p < 0.05) were detected between 
the two serum antibody assays and between the serum and oral fluid test results (Table 2).   
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The quantitative results of testing the two sample types (sow serum and litter oral fluids) by 
four PRRSV ELISAs (IgM, IgA, IgG, and Commercial Kit) are presented in Tables 3 and 4.  
No statistically significant differences in serum antibody ELISA S/P ratios were detected 
among farms, but significant differences among parities were observed with the IgG and 
Commercial Kit ELISAs.  Among the oral fluid antibody ELISAs, statistically significant 
differences in IgA S/P ratios were detected among farms and among sows by parity.  
Likewise, differences among S/P ratios were detected among farms using the oral fluid 
Commercial Kit.  As shown in Figures 1 and 2, correlation analyses of the association 
between sample types (sow serum and oral fluid) S/P ratios estimated Pearson’s correlation 
coefficients for each of the four assays:  IgM (r = 0.23), IgA (r = 0.39), IgG (r = 0.73), and 
Commercial Kit (r = 0.68).   
 
DISCUSSION 
The purpose of surveillance is to determine the presence and/or distribution of target 
pathogens in a population over time (Hadorn and Stark, 2008).  When implemented on 
commercial swine farms, surveillance should inform regarding the health status of the 
population and guide targeted, proactive animal health and business decisions.  Despite the 
potential benefits, routine, continuous on-farm surveillance is rare because of the 
inconvenience and cost of collecting and testing individual pig serum samples.   
 
Previous studies have shown a correlation between serum and swine oral fluid diagnostic 
results for PRRSV and other pathogens (Ramirez et al., 2012).  Prickett et al. (2008a,b) 
reported the detection of PRRSV by RT-qPCR in oral fluid samples collected from pens of 
pigs under both research and field conditions.  Kittawornrat et al. (2010, 2013) described the 
pattern of PRRSV shedding and kinetics of the PRRSV antibody responses in oral fluid 
specimens from individually housed boars over time.  Olsen et al. (2013) found that pen-
based oral fluid testing by either antibody ELISA or RT-qPCR greatly improved PRRSV 
detection compared to individual pig serum sampling across a range of within-pen 
prevalences (4% to 36%).  Cumulatively, these studies suggested that surveillance based on 
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oral fluids could be practical in commercial swine herds because of the ease of sample 
collection and the diagnostic performance of assays optimized for the oral fluid matrix.   
 
The purpose of this study was to evaluate the feasibility of a system of PRRSV surveillance 
based on testing oral fluid samples collected from litters of piglets prior to weaning.  For 
comparison, serum samples were collected from each litter's dam.  In total, 600 litter oral 
fluid and 600 litter-matched sow serum samples were collected in four commercial sow herds 
over a period of 4 months.  All samples were tested by PRRSV RT-qPCR and for PRRSV 
antibody using four different antibody ELISAs (IgM, IgA, IgG, and Commercial Kit).   
 
PRRSV RT-qPCR testing found no positive sow serum samples (n = 600), i.e., there was no 
evidence of PRRSV viremia among the sows tested.  However, 9 of the litter oral fluid 
samples (n = 600) were RT-qPCR positive, indicating that one or more of the piglets in these 
9 litters was infected with PRRSV.  Given the small number of positives and the absence of 
clinical signs suggestive of PRRSV infection, it was necessary to confirm that the original 
RT-qPCR results were true positive reactions.  Therefore, the 9 positive oral fluid samples 
and a set of negative control samples consisting of 21 blindly-selected negative oral fluid 
samples and 30 blindly-selected serum samples were submitted for PRRSV RT-qPCR testing 
at a second laboratory.  Retesting at the second laboratory exactly matched the initial results.  
Thereafter, ORF5 sequencing from oral fluids was attempted on the 6 positive samples with 
sufficient volume still remaining for testing.  Of the 6 samples submitted, ORF5 sequencing 
was successful on 2.  Subsequent analysis of the 2 ORF5 sequences showed ≥ 98% 
nucleotide identity with wild-type PRRS viruses isolated from these herds before and/or after 
the study.   
 
The observed RT-qPCR results showing an extremely low rate of PRRSV transmission 
among litters of suckling piglets were compatible with previous field studies on PRRSV 
infections in pre-weaned piglets.  Graham et al. (2013) tested pre-wean piglet serum samples 
(n = 454 piglets in 44 litters) collected in a commercial herd by PRRSV RT-qPCR and found 
2 positive litters; one litter with one positive piglet and one with two positive piglets.  
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Similarly, Cano et al. (2008) detected 13 PRRSV RT-qPCR positive litters among 42 litters 
tested.  Of the 13 positive litters, 8 contained one positive piglet, 2 had 2 positive piglets, and 
3 had ≥ 4 positive piglets.   
 
Evaluation of antibody responses in sow serum and piglet oral fluid samples from PRRSV 
RT-qPCR positive litters provided insight into the RT-qPCR results.  Previous research has 
described the appearance of anti-PRRSV IgM, IgA, and IgG in serum and oral fluid 
specimens under experimental conditions, but IgM and IgA have not been reported in 
samples collected under field conditions (Kittawornrat et al., 2012a, 2013).  In the present 
study, failure to detect IgM and IgA may be explained by the extensive use of PRRSV MLV 
vaccines and the fact that IgG, both because of its higher concentration and its higher 
affinity, may have out-competed IgM and IgA for antigenic sites in the antibody ELISAs 
(Lee et al., 1995; Makela et al., 1970).  Nevertheless, the significantly higher S/P ratios 
observed in sow serum and oral fluid specimens from PRRSV RT-qPCR positive litters 
suggests that the animals were responding to recent PRRSV infections.  Although all sows 
had been vaccinated against PRRSV, protection against infection with heterologous PRRSV 
isolates is recognized as inconsistent (Benson et al., 2000).  The likelihood of this scenario is 
reinforced by the detection of nucleic acid from wild-type viruses in oral fluid samples.  It 
was not possible to determine the source of infection in this study, but vertical transmission 
between the dam and her piglets can occur either by direct contact or transplacental 
transmission (Christianson et al., 1992; Lager et al., 1997a,b, 1999).  In addition, Wagstrom 
et al. (2001) demonstrated that PRRSV-naïve dams inoculated late in gestation shed virus in 
colostrum and milk, although females with prior exposure to PRRSV did not.  Transmission 
could also have occurred through cross-fostering of infected piglets into negative litters or 
other human interventions, e.g., exposure of animals via virus-contaminated fomites, but the 
low prevalence and sporadic pattern of infection in the population did not reveal a specific 
pattern suggestive of a particular procedure or event.   
 
Cumulatively, the data suggest that PRRSV herd endemnicity is maintained, at least in part, 
by a cycle that involves subclinical PRRSV infection in suckling piglets, with transmission to 
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the population of growing pigs occurring as pigs are moved and mixed post-weaning.  The 
fact that the neonatal infection occurred at a very rate, i.e., 9 of 600 litters, illustrates the 
challenge of on-farm PRRSV surveillance.  Even under these circumstances, however, it was 
possible to detect the presence of the virus and thereby demonstrate the efficiency and 
effectiveness of PRRSV surveillance using pre-weaning oral fluid samples from litters of 
piglets.   
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Table 1.  Summary of sow serum and litter oral fluid sampling by farm over time 
 
 ----------------------------- Calendar week and month -----------------------------  
 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34  
Farm1 May  June July August n 
12 11 • • • 33 33 • 40 36 • • • • • • 153 
23 18 5 17 • • 15 • • 42 24 24 • • • • 145 
34 • • • • • • • • • • • 51 52 32 17 152 
45 • • • • • • • • • • 30 30 35 42 13 150 
n 29 5 17 0 33 48 0 40 78 24 54 81 87 74 30 600 
 
1 All gilts were vaccinated twice prior to placement in the sow farm with "MLV" (Ingelvac 
MLV®, Boehringer Ingelheim Vetmedica, Inc., St. Joseph. MO) 
2 Vaccinated at calendar weeks 9 and 13 with "ATP" (Ingelvac ATP®, Boehringer Ingelheim 
Vetmedica, Inc., St. Joseph. MO) 
3 Vaccinated with "ATP" at calendar weeks 1 and 4, and then "MLV" at calendar week 5 
4 Vaccinated with "ATP" at calendar weeks 2, 20, and 24 
5 Vaccinated with "ATP" at calendar week 1 and "MLV" at calendar week 5 
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Table 2.  Comparison of qualitative results between assays and sample types  
 
PRRSV antibody assay 
(sample matrix)  
n = 600 
Negative 
S/P < 0.4 
Positive 
S/P ≥ 0.4 % Positive 
Statistically significant 
pairwise comparisons 
(Cochran’s Q, p < 0.05) 
1.  Kit1 (sow serum) 157 443 73.8% 2,3,4 
2.  Kit2 (litter oral fluid) 6 594 99.0% 1,3 
3.  IgG3 (sow serum) 127 473 78.8% 1,2,4 
4.  IgG3 (litter oral fluid) 21 579 96.5% 1,3 
 
1 PRRS X3 Ab Test (IDEXX Laboratories, Inc., Westbrook, ME) 
2 PRRS Oral Fluids Ab Test (IDEXX Laboratories, Inc., Westbrook, ME) 
3 PRRS X3 Ab Test (IDEXX Laboratories, Inc., Westbrook, ME) modified to detect anti-
PRRSV antibody IgG in serum and oral fluid specimens (Kittawornrat et al., 2012) 
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Table 3.  Sow serum and litter oral fluid anti-PRRSV antibody testing results 
 
 
 
n 
Mean serum antibody ELISA S/P ratio (SEM) Mean oral fluid antibody ELISA S/P ratio (SEM) 
 IgM1 IgA1 IgG1 Commercial kit2 IgM
1 IgA1 IgG1 Commercial kit3 
F
a
r
m
 
1 153 0.21 (0.02) 0.25 (0.04) 0.99 (0.05) 0.98 (0.06) 0.00 (0.01) 0.05 (0.01)a 2.73 (0.12) 5.27 (0.21)a 
2 145 0.24 (0.03) 0.21 (0.04) 1.10 (0.05) 1.09 (0.07) 0.01 (0.01) 0.05 (0.01)a 2.61 (0.11) 5.06 (0.21)a,b 
3 152 0.20 (0.02) 0.17 (0.02) 0.92 (0.05) 0.91 (0.06) 0.00 (0.01) 0.02 (0.01)b 2.00 (0.11) 3.86 (0.21)c 
4 150 0.23 (0.02) 0.16 (0.02) 0.97 (0.06) 0.99 (0.07) 0.00 (0.01) 0.05 (0.01)a 2.19 (0.11) 4.30 (0.21)b,c 
S
o
w
 
p
a
r
i
t
y
 
1 169 0.23 (0.02) 0.15 (0.02) 0.99 (0.06)a,b,c 1.04 (0.07)a 0.00 (0.01) 0.06 (0.01)a 2.31 (0.12) 4.49 (0.21) 
2 113 0.22 (0.02) 0.19 (0.03) 0.86 (0.06)c 0.83 (0.07)c 0.00 (0.01) 0.05 (0.01)a,b 2.25 (0.13) 4.46 (0.24) 
3 91 0.20 (0.03) 0.16 (0.02) 1.06 (0.06)a,b 1.05 (0.08)a,b 0.00 (0.01) 0.01 (0.01)c 2.46 (0.16) 4.70 (0.29) 
4 93 0.20 (0.03) 0.22 (0.06) 0.91 (0.05)b,c 0.86 (0.06)b,c 0.00 (0.01) 0.02 (0.01)b,c 2.34 (0.14) 4.51 (0.25) 
5 57 0.21 (0.03) 0.29 (0.06) 1.21 (0.07)a 1.21 (0.08)a 0.00 (0.01) 0.04 (0.01)a,b,c 2.62 (0.18) 5.12 (0.34) 
≥6 77 0.26 (0.05) 0.26 (0.08) 1.06 (0.08)a,b,c 1.05 (0.09)a,b,c 0.00 (0.01) 0.04 (0.01)a,b,c 2.45 (0.16) 4.82 (0.28) 
Mean 600 0.22 (0.01) 0.20 (0.02) 0.99 (0.03) 0.99 (0.03) 0.00 (0.01) 0.04 (0.01) 2.38 (0.06) 4.62 (0.11) 
 
1  PRRS X3 Ab Test (IDEXX Laboratories, Inc., Westbrook, ME) modified to detect anti-PRRSV antibody isotypes in serum and 
oral fluid specimens (Kittawornrat et al., 2012) 
2  PRRS X3 Ab Test (IDEXX Laboratories, Inc., Westbrook, ME) 
3  PRRS Oral Fluids Ab Test (IDEXX Laboratories, Inc., Westbrook, ME) 
a,b,c Within columns, different superscripted letters denote statistically significant differences between means (p < 0.05) 
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Table 4.  Follow-up testing on matched pairs (sow serum and litter oral fluid) of PRRSV qRT-PCR-positive oral fluid 
samples  
Farm 
Calendar 
week 
Sow  
parity 
Litter 
size 
Serum Ct and S/P ratios (sow) Pre-weaning oral fluid testing results (litter) 
PCR11 PCR22 IgM3 IgA3 IgG3 Kit4 PCR11 PCR22 IgM3 IgA3 IgG3 Kit5 
 1 24 1 11 Neg Neg 0.32 0.09 0.85 0.92 34.3 34.9 0.03 0.31 3.38 7.75 
 1 25 1 12 " "  " " 0.72 0.19 0.33 0.31 36.5 37.1 0.01 0.03 0.58 1.24 
 1 27 2 9 " " " " 0.47 1.54 1.76 1.75 27.2 27.2 0.05 0.14 5.44 8.83 
 1 27 1 10 " " " " 0.00 0.28 2.08 2.68 34.6 36.1 0.05 0.22 4.13 6.98 
 2 20 5 11 " " " " 0.08 0.05 2.09 2.14 33.6 36.4 0.00 0.04 4.85 8.26 
 26 30 5 10 " " " " 0.08 1.26 2.22 2.91 29.0 30.7 0.04 0.20 2.14 4.22 
 3 31 5 11 " " " " 0.39 0.10 1.02 1.11 33.6 34.7 0.01 0.01 1.26 1.92 
 36 32 1 9 " " " " 0.94 0.07 2.36 2.75 27.9 29.1 0.08 0.39 5.97 8.21 
 3 33 1 11 " " " " 0.22 0.14 2.21 2.61 29.6 30.6 0.01 0.06 2.81 6.84 
 
1 Cycle threshold (Ct) value ≥37 considered negative (tested by Iowa State University Veterinary Diagnostic Laboratory, Ames, IA) 
2  Cycle threshold (Ct) value ≥38 considered negative (tested by Tetracore Inc., Rockville, MD) 
3 PRRS X3 Ab Test (IDEXX Laboratories, Inc., Westbrook, ME) modified to detect anti-PRRSV antibody isotypes in serum and oral fluid specimens 
(Kittawornrat et al., 2012) 
4  PRRS X3 Ab Test (IDEXX Laboratories, Inc., Westbrook, ME) 
5  PRRS Oral Fluids Ab Test (IDEXX Laboratories, Inc., Westbrook, ME) 
6 PRRSV ORF5 sequences obtained from litter oral fluid samples (see Table 5) 
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Table 5.  Pair-wise comparison of PRRSV isolates based on ORF5 nucleotide percent identity 
 
Isolate 
Farm 2 
11/2010 
Farm 21 
07/2011 
Farm 2 
11/2011 
Farm 2 
03/2012 
Farm 3 
12/2010 
Farm 31 
08/2011 
ATP2 MLV3 VR2332 
Farm 2 
11/2010
 99.0 98.6 99.3 86.5 86.0 89.0 87.3 87.3 
Farm 2 
07/2011
99.0  98.1 98.6 86.2 85.7 88.3 86.7 86.7 
Farm 2 
11/2011
98.6 98.1  99.3 86.4 86.2 88.3 86.4 86.4 
Farm 2 
03/2012
99.3 98.6 99.3  86.5 86.4 88.7 86.7 86.7 
Farm 3 
12/2010
86.5 86.2 86.4 86.5  99.0 89.3 86.0 86.0 
Farm 3 
08/2011
86.0 85.7 86.2 86.4 99.0  88.8 85.5 85.5 
ATP2 89.0 88.3 88.3 88.7 89.3 88.8  90.2 90.5 
MLV3 87.3 86.7 86.4 86.7 86.0 85.5 90.2  99.3 
VR2332 87.3 86.7 86.4 86.7 86.0 85.5 90.5 99.3  
 
1 Sequences from Farm 2 isolate 07/2011 and Farm 3 isolate 08/2011 were derived from litter oral fluid samples collected in the 
study.  Other Farm 2 and Farm 3 viruses were derived from sow serum samples collected in association with abortions and 
submitted for routine testing at veterinary diagnostic laboratories.   
2 Ingelvac ATP®, Boehringer Ingelheim Vetmedica, Inc., St. Joseph. MO 
3 Ingelvac MLV®, Boehringer Ingelheim Vetmedica, Inc., St. Joseph. MO  
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Figure 1.  Correlation between paired sow serum and litter oral fluid sample S/P ratios.  
Samples were tested using a PRRSV IgG ELISA, with procedures adapted to 
each sample matrix.   
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Figure 2.  Correlation between paired sow serum and litter oral fluid sample S/P ratios.  
Samples were tested using commercial ELISA kits, i.e., PRRS X3 Ab Test 
(serum) or PRRS Oral Fluids Ab Test (oral fluid), IDEXX Laboratories, Inc., 
Westbrook, ME.   
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CHAPTER 7.  GENERAL CONCLUSIONS 
Current surveillance and monitoring systems (MOSS) in swine populations are primarily 
based on blood sampling - a labor-intensive sampling method.  As a result, routine 
surveillance is generally cost-prohibitive and under-utilized.  Cost-effective methods of 
disease monitoring are needed to support animal health and business decisions at the herd 
level, improve the quality of field research, and provide timely information on endemic and 
foreign animal diseases in the national swine herd. 
 
Oral fluid samples are increasingly used for the surveillance of pathogens in commercial 
swine operations in North America.  For example, the specimen type "swine oral fluid" was 
entered into the Iowa State University Veterinary Diagnostic Laboratory (ISU VDL) 
information management system in February, 2010.  During the remainder of 2010, 10,329 
oral fluid specimens were received for testing.  The oral fluid sample submissions increased 
to 32,544 in 2011 60,050 in 2012, respectively.  If the current level of submissions is 
maintained, the laboratory will receive >80,000 oral fluid samples in 2013.   
 
The research described in this dissertation confirmed earlier research on the detection of 
porcine reproductive and respiratory syndrome virus (PRRSV) in oral fluids and expanded on 
earlier work by demonstrating that a commercial serum antibody ELISA could be adapted to 
oral fluid specimens and used routinely in commercial diagnostic laboratories for the 
detection of anti-PRRSV antibody (Chapter 3).  Importantly, the protocol that was developed 
for the PRRSV oral fluid IgG ELISA was highly repeatable, reproducible, and compatible 
with the routine performance of the assay in high throughput diagnostic laboratories (Chapter 
4).  Furthermore, the diagnostic performance of the assay suggested the possibility of a cost-
effective method to routinely monitor commercial swine populations for maternal antibody, 
vaccination compliance, and herd immune parameters using oral fluid sampling.  Subsequent 
work (Chapter 5) provided a foundation for understanding assay performance in the context 
of PRRSV replication, shedding and the anti-PRRSV antibody response.  This work provided 
the basis of a commercial PRRSV oral fluid antibody ELISA that is now available globally 
(PRRSV Oral Fluids Ab ELISA, IDEXX Laboratories, Inc., Westbrook, ME).  In addition, 
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we began the process of transitioning this research to the field in this dissertation research.  
Specifically, as shown in Chapter 6, PRRSV surveillance was conducted easily, effectively, 
and cheaply using pre-weaning oral fluid samples from litters of piglets.  This provided 
evidence that on-farm, real-time surveillance could be conducted using this approach, 
thereby achieving the goal of cost-effective methods of MOSS.   
 
The research presented in this dissertation advanced the use of oral fluid specimens for 
PRRSV surveillance in swine production systems, but many issues, questions, and topics 
remain to be addressed.  These generally fall into two categories:  application and 
development. The application category contains questions that are simple to express, but will 
require hard data to answer:  “How many oral fluid samples to collect?”, “How often should 
testing be repeated”, and “Which barn or room or pen should be collected”.  The 
development category represents the future of oral fluid testing.  That is, having successfully 
produced one commercial oral fluid antibody ELISA, what other tests could be developed 
and commercialized to detect antibodies, pathogens, hormones, or drugs in oral fluids?  
Although there is much to be done, oral fluid sampling in swine populations would seem to 
be poised to fulfill the need to obtain the real-time data crucial to the health, productivity, and 
management of pig herds. 
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